Document:

<Page>

                                                                   Exhibit 10.20

    [CERTAIN MATERIAL (INDICATED BY A [*CON*]) HAS BEEN OMITTED FROM THIS
    DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION]

                             SERVICES AGREEMENT FOR
                               CHIRON CORPORATION

This Services Agreement ("AGREEMENT") is made effective as of February 7, 2000
("Effective Date") by and between Chiron Corporation ("CHIRON"), a Delaware
corporation with its principal place of business at 4560 Horton Street,
Emeryville, California 94608 and Mimotopes Pty. Ltd. ("MIMOTOPES"), an
Australian proprietary company with its principal place of business at 11
Duerdin Street, Clayton, Victoria 3168 Australia.

WHEREAS:

         By the terms of an Asset Purchase Agreement dated as of the Effective
Date of this Agreement ("PURCHASE AGREEMENT"), Chiron transferred certain of the
assets of its wholly owned subsidiary Chiron Technologies Pty. Ltd. ("CTPL") to
Mimotopes.

         Following such transfer, Chiron desires to have Mimotopes perform
certain services for Chiron.

THEREFORE,

         Chiron, hereby, contracts with Mimotopes to perform new services as
well as services formerly provided by CTPL to Chiron.

         1.       DESCRIPTION OF SERVICES

                  1.1      SERVICES. Mimotopes shall use reasonable commercial
efforts to provide at Chiron's request all services and technical assistance in
the synthesis and design of molecules in the support of Chiron's drug discovery
program for (a) projects involving discovery and development of (i) [ * CON * ]
and (ii) [ * CON * ]; and (b) other projects which may be mutually agreed to by
the parties as described below in this Section (the "SERVICES"). From time to
time, Chiron shall nominate such fields of research or specification of
compounds to be synthesized by submitting a written work order to Mimotopes, for
approval, which approval shall not be unreasonably withheld. The parties shall
mutually agree to a written research plan for each project outlining the
Services to be performed by Mimotopes for each such project. Mimotopes shall not
be required to provide Services that require staffing beyond the number of FTE's
set forth in Section 1.2 ("Employees"). The parties specifically agree that
Mimotopes is not responsible for any negligence, errors or omissions by CTPL in
CTPL's performance of the services prior to the Effective Date of this
Agreement.

                  1.2      EMPLOYEES. Mimotopes shall provide a minimum of
[ * CON * ] Full-Time Equivalents ("FTE's") to perform the Services (as defined
in Section 1.3 herein) during the first year of this Agreement, [ * CON * ]
FTE's to perform the Services during the second year of this Agreement and
[ * CON * ] FTE's to perform the Services during the third year of this
Agreement. Chiron reserves the right in its sole discretion to designate each of
the initial FTE's, further identified as the FTE Team and listed in ATTACHMENT
A. Subsequently, Chiron shall have the right to approve each additional or
replacement FTE on the basis of qualifications, with such approval not to be
unreasonably withheld.

                                       1
<Page>

                  1.3      TERM. The Services shall be provided for a term of
three (3) years commencing on the Effective Date ("TERM"), unless earlier
amended or extended in accordance with the terms and conditions of Article 9
("Amendment, Termination and Survival") herein.

         2.       WORK PRODUCT AND MATERIALS.

                  2.1      All data, reports, materials, inventions and
discoveries generated or created by Mimotopes arising from its conduct of the
Services which are conceived or reduced to practice during the Term of this
Agreement are hereafter collectively referred to as "WORK PRODUCT". Chiron shall
own all right, title and interest in the Work Product, except for any Process
Improvements (as defined below), which shall be the sole and exclusive property
of Mimotopes. A Process Improvements is any new, improved or modified technique,
process, method, instrument or equipment or similar know-how, including without
limitation new chemical processes, synthesis protocols, linker systems, cleavage
methods, or analytic techniques, developed or created by Mimotopes which is not
specific to Chiron Chemical Matter. Chiron will retain a non-exclusive,
royalty-free license to use any Process Improvements, with the right to
sublicense. Work Product will be deemed Confidential Information as defined in
Article 4 ("Confidentiality and Non-Use Obligation") herein. Subject to the
provisions of the Purchase Agreement, this Agreement (i) does not convey to
Mimotopes any right, title or interest to or in any patents, patent
applications, know-how (whether patentable or unpatentable) or other
intellectual property rights of Chiron; and (ii) does not convey to Chiron any
right, title or interest to or in any patents, patent applications, know-how
(whether patentable or unpatentable) or other intellectual property rights of
Mimotopes.

                  2.2.     Mimotopes shall provide to Chiron a written report on
the current status of the Services, FTE's and Work Product, including but not
limited to a financial accounting and a project review. The report shall be made
within fifteen days of the close of each calendar quarter. Additionally,
Mimotopes shall send to Chiron, annually and at its expense, not more than
[ * CON * ] ([ * CON * ]) people-trips of lead scientists to participate in a
project meeting. If Chiron desires, and so requests, more people-trips within
any contract year, then either (i) Chiron will send its personnel to Mimotopes'
facility in Australia for such meeting; or (ii) Chiron will reimburse Mimotopes
for all out-of-pocket costs associated with such travel.

                  2.3      Mimotopes shall keep separate laboratory notebook
records, prepared and witnessed according to standard laboratory practices, of
all work performed under this Agreement. These notebooks and other records shall
be owned, properly maintained and stored by Mimotopes. Upon written request by
Chiron, Mimotopes shall (i) make such laboratory notebook records reasonably
available to Chiron for on-site inspection at Mimotopes; (ii) provide to Chiron
copies of the relevant portions of such laboratory notebook records as
reasonably needed by Chiron for routine patent protection (e.g., filing and
prosecution) or other purposes; and (iii) in the event Chiron needs the original
laboratory notebook records for litigation or patent interference purposes,
Mimotopes shall make such original records available to Chiron. Mimotopes shall
ordinarily bear the cost of the activities set forth in (i), (ii) and (iii);
provided, however, that in cases where Mimotopes in its reasonable discretion
determines that Chiron's requests become a significant burden in terms of time
and/or expense, then Mimotopes reserves the right to require Chiron to reimburse
Mimotopes for such activities.

                                       2
<Page>

                  2.4      Mimotopes shall cooperate with Chiron and make its
scientists reasonably available for purposes of filing, prosecuting and
defending patent applications arising out of the Work Product. Mimotopes shall
ordinarily bear the cost of the activities set forth in this Section 2.4;
provided, however, that in cases where Mimotopes in its reasonable discretion
determines that Chiron's requests become a significant burden in terms of time
and/or expense, then Mimotopes reserves the right to request Chiron to reimburse
Mimotopes for such activities.

         3.       COMPENSATION. As compensation for Mimotopes' conduct of the
Services, Chiron shall pay Mimotopes in United States dollars at the rate of
[ * CON * ] dollars ($[ * CON * ]) per FTE per year. In any case, the payment
shall not exceed [ * CON * ] dollars ($[ * CON * ]) in the first year of this
Agreement, [ * CON * ] dollars ($[ * CON * ]) in the second year of this
Agreement and [ * CON * ] dollars ($[ * CON * ]) in the third year of this
Agreement. Chiron's first year payment shall be made within thirty (30) days
after the Effective Date of this Agreement. All other payments shall be made in
advance at the beginning of each subsequent year of the Term, that is, on the
first and second anniversary, of this Agreement.

         4.       CONFIDENTIALITY AND NON-USE OBLIGATIONS.

                  4.1      CONFIDENTIAL INFORMATION. During the course of
activities contemplated by this Agreement, either party, its employees, agents,
representatives and consultants (collectively, "Recipient") shall have access to
certain confidential and proprietary information ("Confidential Information") of
the other party ("Dislcoser"). Confidential Information shall include without
limitation Chiron's lead compounds (the "Chiron Chemical Matter") or either
party's proprietary materials and technologies, research and development data
and plans, business or research strategies, trade secrets and material
embodiments thereof, and manufacturing processes and technologies. Chiron and
Mimotopes each retains exclusive title to its Confidential Information.

                  4.2      CONFIDENTIALITY AND NON-USE. The Recipient shall
maintain the Discloser's Confidential Information in confidence. The Recipient
shall use the Discloser's Confidential Information solely for performing or
evaluating the Services unless otherwise mutually agreed in writing. Upon
request by the Discloser, the Recipient shall return all Confidential
Information, including all copies and extracts thereof, to the Discloser;
provided, however, that Mimotopes will be entitled to retain one copy of any
Work Product.

                  4.3      EXCLUSIONS. The Recipient's obligations of
confidentiality and non-use shall not apply to any information that: (i) is
shown by contemporaneous documentation of the Recipient to have been in its
rightful possession prior to receipt from the Discloser; (ii) is or becomes,
through no fault of the Recipient, publicly known; (iii) is furnished to the
Recipient by a third party without breach of a duty to the Discloser; (iv) the
Recipient is required to disclose such information by law, order or regulation
of a governmental agency or a court of competent jurisdiction or international
authority (after providing the Discloser with reasonable notice of such
requirement to divulge and with an opportunity to obtain a protective order; or
(v) was or is independently developed by the Recipient without reference to the
Discloser's Confidential Information.

                                       3
<Page>

         5.       COMPLIANCE WITH LAW; STANDARD OF CARE. Mimotopes shall comply
with all applicable laws, ordinances, rules and regulations pertaining to its
performance of the Services. Mimotopes shall perform the Services in accordance
with the reasonable commercial standards of care and diligence practiced by
recognized firms in providing services of a similar nature and shall provide the
reasonable commercial skill and judgment of its employees in providing the
Services.

         6.       NOTICES. All notices and other official communications
hereunder shall be in writing and shall be deemed given if delivered personally
or by commercial delivery service, or within seventy-two (72) hours after being
mailed by registered or certified mail (return receipt requested) or sent via
facsimile (with confirmation of receipt) to the parties at the following
addresses (or at such other address for a party as shall be specified by like
notice):

                  In the case of Mimotopes:

                           Mimotopes Pty. Ltd.
                           11 Duerdin Street
                           Clayton, Victoria 3168 Australia
                           Attention:  Managing Director
                           Fax:     61-3-9565-1199
                           Tel:     61-3-9565-1111

                  with copies to:

                           MitoKor
                           11494 Sorrento Valley Road
                           San Diego, CA  92121
                           Attention:  Chief Executive Officer
                           Fax:     858-793-7805
                           Tel:     858-793-7800

                  In the case of Chiron:

                           Chiron Corporation
                           4560 Horton Street
                           Emeryville, California 94608
                           Attention:  Office of the General Counsel
                           Fax:     510-654-5360

                           cc: President, Chiron Technologies
                           Fax:     510-923-[ * CON * ]

                           cc: Dr. [ * CON * ]
                           Fax:     (510) 923-[ * CON * ]

                                       4
<Page>

         7.       INDEMNIFICATION.

                  7.1      To the extent permitted by applicable law, and except
to the extent caused by the negligence or willful misconduct of Chiron, or its
employees, agents or representatives, Mimotopes shall indemnify, defend, protect
and hold Chiron, and its directors, officers, stockholders, employees, agents
and representatives, harmless from any and all liability, damages, causes of
action, loss, cost or expense (including but not limited to, reasonable
attorneys' fees) (collectively, "Losses") arising at any time out of Mimotopes'
negligence or willful misconduct performing under this Agreement. For the
avoidance of doubt, Chiron specifically agrees that Mimotopes' indemnification
does not, in any circumstances, extend to Losses arising out of Chiron's and/or
any third party's sale or use of any products which incorporate, or are produced
using, the Work Product or any derivative or modification thereof.

                  7.2      To the extent permitted by applicable law, and except
to the extent caused by the negligence or willful misconduct of Mimotopes, or
its employees, agents or representatives, Chiron shall indemnify, defend,
protect and hold Mimotopes, and its directors, officers, stockholders,
employees, agents and representatives, harmless from any and all Losses arising
at any time out of (i) Chiron's negligence or willful misconduct in performing
under this Agreement; or (ii) Chiron's and/or any third party's sale or use of
any products which incorporate, or are produced using, the Work Product or any
derivative or modification thereof.

                  7.3      The party seeking indemnification under Section 7.1
or 7.2 (the "Indemnified Party") agrees to give prompt notice to the party
against whom indemnity is sought (the "Indemnifying Party") of the assertion of
any claim, or the commencement of any suit, action or proceeding in respect of
which indemnity may be sought under such section. The Indemnifying Party may,
and at the request of the Indemnified Party shall, participate in and control
the defense of any such third party suit, action or proceeding at its own
expense. The Indemnifying Party shall not be liable under Section 7.1 or 7.2 for
any settlement effected without its consent of any claim, litigation, or
proceeding in respect of which indemnity may be sought hereunder.

         8.       INDEPENDENT CONTRACTOR. Mimotopes is an independent contractor
engaged by Chiron to perform the Services in accordance with the provisions of
this Agreement, and the relationship hereby created is specifically governed by,
limited to, and subject to all of the terms and conditions contained in this
Agreement. The parties further agree that Chiron does not have the authority to
hire or fire employees of Mimotopes, nor does Chiron determine the rate or
method of pay of such employees. Additionally, nothing contained in this
Agreement shall entitle either party to the right or authority to make any
representation on behalf of or bind the other party to others in any manner,
except as may be specifically authorized in writing by the other party. Neither
party may make any representations or commitments on the other's behalf, nor may
either party use the other party's name or trademarks in any public disclosure,
without the named party's prior written consent.

         9.       AMENDMENT, TERMINATION AND SURVIVAL.

                  9.1.     This Agreement may be amended or renewed only with
the written agreement of both parties.

                                       5
<Page>

                  9.2      Either party may terminate this Agreement if such
party provides written notice of Material Breach to the breaching party and such
Material Breach has not been remedied within thirty (30) days after the date of
such notice. In the case of Mimotopes, a Material Breach of this Agreement shall
be defined as a substantial failure by Mimotopes to meet any material mutually
agreed upon written performance criteria or a failure of Mimotopes to provide
the required number of FTE's. In the case of Chiron, a Material Breach of this
Agreement shall be defined as the failure to make any required payment. Upon
early termination of this Agreement under this Section by either party, (i) if
Chiron has made payment for Services which have not yet been performed, then
Chiron shall be entitled, as damages, to a pro-rated return of the compensation
it has paid under Section 3 ("Compensation") of this Agreement; or (ii) if
Mimotopes has not yet been paid for Services which it has performed, then
Mimotopes shall be entitled to a pro-rated payment of such compensation for the
period in which the Services were performed.

                  9.3      Those terms and obligations which by their nature
should continue shall survive any termination or expiration of this Agreement,
including without limitation the terms and obligations of Articles 1.1
("Services"), 2 ("Work Product and Materials"), 4 ("Confidentiality and
Non-Use"), 7 ("Indemnification"), 8 ("Independent Contractor") and 13 ("Warranty
Disclaimer; Consequential Damages").

         10.      WAIVER AND SEVERABILITY. No waiver of any of the provisions of
this Agreement shall be deemed, or shall constitute, a waiver of any other
provision, whether or not similar, nor shall any waiver constitute a continuing
waiver. No waiver shall be binding unless executed in writing by the party
making the waiver. This Agreement shall be interpreted as a whole and neither
for or against either party, in accordance with their common meaning, but taking
into account the nature of the Services to be rendered by Mimotopes.

         11.      ASSIGNMENT. This Agreement and any rights under it may be
assigned by Chiron with the prior written consent of Mimotopes, which shall not
be unreasonably withheld. This Agreement and any rights under is may not be
assigned by Mimotopes, except that either party may assign its rights and
obligations under this Agreement, in whole or in part, to a successor in
interest, in whole or in part, of the business to which this Agreement relates.
Such assignment shall be binding upon and inure to the benefit of the parties,
their successors and permissible assigns.

         12.      ENTIRE AGREEMENT. This Agreement contains all the
representations and the entire agreement between the parties with respect to the
Services identified herein. The terms and conditions of the Purchase Agreement
shall continue to apply to all other aspects of the relationship between the
parties not specifically addressed in this Agreement.

         13.      WARRANTY DISCLAIMER; CONSEQUENTIAL DAMAGES. ANY WORK PRODUCT
IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. MIMOTOPES MAKES NO
REPRESENTATION OR WARRANTY THAT THE WORK PRODUCT WILL NOT INFRINGE ANY PATENT OR
OTHER PROPRIETARY RIGHTS. IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY
INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING FROM THIS AGREEMENT.

                                       6
<Page>

         14.      COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original as against any party
whose signature appears on such counterpart and all of which shall be considered
on and the same agreement and shall become effective when one or more
counterparts have been signed by each of the parties and delivered to the other
party, it being understood that each party need not sign the same counterpart.
This Agreement may be executed by facsimile signature as long as the party so
executing commits to deliver an original signature within twenty (20) days.

         15.      GOVERNING LAW; VENUE AND JURISDICTION. This Agreement shall be
governed and construed in accordance with the laws of the State of California
without regard to any applicable conflicts of laws principles. Any legal action
arising under this Agreement shall be resolved in the courts located in San
Diego, California if brought by Chiron and in San Francisco, California if
brought by Mimotopes.

         16.      THIRD PARTY BENEFICIARIES. Nothing contained in this Agreement
is intended to confer upon any person other than the parties hereto and their
respective successors and permitted assigns, any rights, remedies or obligations
under, or by reason of this Agreement.

[Remainder of this page intentionally left blank]

                                       7
<Page>

         This Agreement is executed by the parties to be effective as of the
Effective Date.

CHIRON CORPORATION                       MIMOTOPES PTY. LTD.

By:                                      By:
       ------------------------------             ------------------------------

Name:                                    Name:
       ------------------------------             ------------------------------

Title:                                   Title:
       ------------------------------             ------------------------------

                                       8
<Page>

                                  ATTACHMENT A
                          FTE TEAM FOR CHIRON PROJECTS

The following FTE's will work 100% of their time on Chiron projects and the
entire team shall not be changed without Chiron's written approval.

[ * CON * ]

                                       9
<Page>

October 3, 2000

Walter H. Moos, Ph.D.
Chairman
Mimotopes Pty. Ltd.
11494 Sorrento Valley Road
San Diego, CA 92121

Dear Dr. Moos:

In response to your request, and pursuant to the Services Agreement entered into
by Mimotopes Pty. Ltd. and Chiron Corp. effective February 7, 2000 and the Asset
Purchase Agreement executed concurrently by the parties, the parties hereby
agree to amend such services specifically relating to Mimotopes' employee
staffing allocations during the term of that agreement.

Specifically, the parties agree that Section 1.2 of the Services Agreement is
hereby amended in entirety as follows:

1.2 EMPLOYEES. Mimotopes shall provide a minimum of [ * CON * ] Full-Time
Equivalents ("FTE's") to perform the Services (as defined in Section 1.3 herein)
during each full year of this Agreement. Chiron reserves the right in its sole
discretion to designate each of the initial FTE's, further identified as the FTE
Team and listed in Attachment A. Subsequently, Chiron shall have the right to
approve each additional or replacement FTE on the basis of qualifications, with
such approval not to be unreasonably withheld.

If you agree to this modification, please indicate your approval by signing
below.

Sincerely,

Sean O'Connell
Chiron Corporation

I agree:

------------------------------                       ------------
Walter H. Moos, PhD.                                 Date
Chairman of the Board of Directors
Mimotopes Pty. Ltd.<Page>

                                                                   Exhibit 10.21

    [CERTAIN MATERIAL (INDICATED BY A [*CON*]) HAS BEEN OMITTED FROM THIS
    DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION]

                          LICENSE AND OPTION AGREEMENT

                                 BY AND BETWEEN

                          APOLLO BIOPHARMACEUTICS, INC.

                                       AND

                       AMERICAN HOME PRODUCTS CORPORATION

              ACTING THROUGH ITS WYETH-AYERST LABORATORIES DIVISION

                                FEBRUARY 8, 1999
<Page>

                                TABLE OF CONTENTS

<Table>
<S>      <C>                                                                                           <C>
1.       DEFINITIONS.....................................................................................1

         1.1      "AFFILIATE(S)".........................................................................1
         1.2      "APOLLO NCE"...........................................................................1
         1.3      "APOLLO PATENT RIGHTS".................................................................2
         1.4      "COMMERCIALLY REASONABLE EFFORTS"......................................................2
         1.5      "CONTROL" OR "CONTROLLED"..............................................................2
         1.6      "EFFECTIVE DATE".......................................................................2
         1.7      [ * CON * ]............................................................................2
         1.8      [ * CON * ]............................................................................3
         1.9      "FIELD"................................................................................3
         1.10     "FIRST COMMERCIAL SALE"................................................................3
         1.11     [ * CON * ]............................................................................3
         1.12     "HSR ACT"..............................................................................3
         1.13     "INTERIM CLINICAL EVALUATION POINT" OR "ICE"...........................................3
         1.14     "IND FILING"...........................................................................3
         1.15     "IND TRACK"............................................................................3
         1.16     "KNOW-HOW".............................................................................3
         1.17     "LICENSED PRODUCT(S)"..................................................................3
         1.18     "MAJOR COUNTRY"........................................................................4
         1.19     "NET SALES"............................................................................4
         1.20     [ * CON * ]............................................................................5
         1.21     [ * CON * ]............................................................................5
         1.22     "OPTION TERM"..........................................................................5
         1.23     "PRODUCT"..............................................................................5
         1.24     "PRODUCT TYPE".........................................................................5
         1.25     "REGULATORY APPROVAL"..................................................................5
         1.26     "REGULATORY AUTHORITY".................................................................5
         1.27     "SCIENTIFIC REVIEW COMMITTEE"..........................................................6
         1.28     "START PHASE III"......................................................................6
         1.29     "TERRITORY"............................................................................6
         1.30     "THIRD PARTY(IES)".....................................................................6
         1.31     "TYPE A PRODUCT".......................................................................6
         1.32     "TYPE B PRODUCT".......................................................................6
         1.33     "TYPE C PRODUCT".......................................................................6
         1.34     "TYPE D PRODUCT".......................................................................6
         1.35     "TYPE E PRODUCT".......................................................................6
         1.36     [ * CON * ]............................................................................6
         1.37     "VALID CLAIM"..........................................................................6

2.       RIGHTS GRANTED..................................................................................7

         2.1      EXCLUSIVE LICENSE......................................................................7
         2.2      SUBLICENSES............................................................................7
         2.3      GRANT OF OPTIONS.......................................................................7
                  2.3.1    TYPE C PRODUCTS...............................................................8
                  2.3.2    TYPE D PRODUCTS...............................................................8
                  2.3.3    TYPE E PRODUCTS...............................................................8
         2.4      EXERCISE OF OPTIONS....................................................................8
         2.5      [ * CON * ]............................................................................9
         2.6      HSR FILING AND APPROVALS...............................................................9
                  2.6.1    HSR FILING....................................................................9
                  2.6.2    APOLLO'S AND AHPC'S OBLIGATIONS..............................................10
                  2.6.3    ADDITIONAL APPROVALS.........................................................10

                                       i
<Page>

<S>      <C>                                                                                           <C>
                  2.6.4    FAILURE TO CLOSE.............................................................10
         2.7      U.S. MANUFACTURE......................................................................11

3.       CONSIDERATION..................................................................................11

         3.1      LICENSE FEE...........................................................................11
         3.2      ADDITIONAL FEES - TYPE A PRODUCT......................................................11
         3.3      ADDITIONAL FEES - TYPE B PRODUCTS.....................................................12
         3.4      OPTION TERM EXTENSION FEES............................................................12
         3.5      OPTION EXERCISE FEE...................................................................12
                  3.5.1    TYPE C PRODUCTS..............................................................12
                  3.5.2    TYPE D PRODUCTS..............................................................12
                  3.5.3    TYPE E PRODUCTS..............................................................13
         3.6      ADDITIONAL FEES - TYPE C PRODUCTS.....................................................13
         3.7      ADDITIONAL FEES - TYPE D PRODUCTS.....................................................13
         3.8      ADDITIONAL FEES - TYPE E PRODUCTS.....................................................14
         3.9      ROYALTIES.............................................................................14
                  3.9.1    ROYALTY RATES -- TYPE A PRODUCTS.............................................14
                  3.9.2    ROYALTY RATES -- TYPE B PRODUCTS.............................................15
                  3.9.3    ROYALTY RATES -- TYPE C PRODUCTS.............................................15
                  3.9.4    ROYALTY RATES -- TYPE D PRODUCTS.............................................15
                  3.9.5    ROYALTY RATES -- TYPE E PRODUCTS.............................................16
                  3.9.6    TERM AND SCOPE OF ROYALTY OBLIGATIONS........................................16
                  3.9.7    THIRD PARTY LICENSES.........................................................16
         3.10     REPORTS AND PAYMENT OF ROYALTY........................................................17
                  3.10.1   ROYALTIES PAID QUARTERLY.....................................................17
                  3.10.2   METHOD OF PAYMENT............................................................17
         3.11     MAINTENANCE OF RECORDS; AUDITS........................................................17
                  3.11.1   RECORD KEEPING BY AHPC.......................................................17
                  3.11.2   AUDIT BY APOLLO..............................................................18
                  3.11.3   UNDERPAYMENTS/OVERPAYMENTS...................................................18
                  3.11.4   RECORD KEEPING BY SUBLICENSEE................................................19
                  3.11.5   CONFIDENTIALITY..............................................................19
         3.12     TAXES AND WITHHOLDING.................................................................19
         3.13     FOREIGN EXCHANGE......................................................................19
         3.14     INTEREST..............................................................................19

4.       PRODUCT DEVELOPMENT AND COMMERCIALIZATION......................................................19

         4.1      DEVELOPMENT AND REGISTRATION OF LICENSED PRODUCTS.....................................19
                  4.1.1    DILIGENCE OBLIGATION.........................................................19
                  4.1.2    TYPE D PRODUCTS..............................................................20
                  4.1.3    TYPE E PRODUCTS..............................................................20
         4.2      EXTENSION OF TIME.....................................................................20
         4.3      COMMERCIALIZATION OF LICENSED PRODUCTS................................................20
         4.4      STATUS REPORTS........................................................................20
         4.5      APOLLO DEVELOPMENT AND REPORTING OBLIGATIONS..........................................21
                  4.5.1    DEVELOPMENT..................................................................21
                  4.5.2    SCIENTIFIC REVIEW COMMITTEE; REPORTS.........................................21

5.       REGULATORY MATTERS.............................................................................22

         5.1      REGULATORY FILINGS....................................................................22
         5.2      ADVERSE EVENT REPORTING...............................................................22

                                       ii
<Page>

<S>      <C>                                                                                           <C>
6.       INTELLECTUAL PROPERTY..........................................................................22

         6.1      FILING, PROSECUTION AND MAINTENANCE OF APOLLO PATENT RIGHTS...........................22
         6.2      OPTION OF AHPC TO PROSECUTE AND MAINTAIN APOLLO PATENT RIGHTS.........................23
         6.3      ENFORCEMENT OF APOLLO PATENT RIGHTS...................................................23
                  6.3.1    NOTICE AND DISCONTINUANCE OF INFRINGEMENT....................................23
                  6.3.2    CONTINUANCE OF INFRINGEMENT..................................................24
         6.4      INFRINGEMENT OF THIRD PARTY PATENTS; THIRD PARTY LICENSES.............................25
                  6.4.1    COURSE OF ACTION.............................................................25
                  6.4.2    AHPC OPTION TO NEGOTIATE.....................................................25
                  6.4.3    APOLLO OPTION TO NEGOTIATE...................................................25
                  6.4.4    THIRD PARTY INFRINGEMENT SUIT................................................25
         6.5      CERTIFICATION UNDER DRUG PRICE COMPETITION AND PATENT RESTORATION ACT.................27
         6.6      ABANDONMENT...........................................................................27
         6.7      PATENT TERM RESTORATION...............................................................27
         6.8      NOTICES REGARDING PATENTS.............................................................28

7.       REPRESENTATIONS AND WARRANTIES.................................................................29

         7.1      REPRESENTATIONS AND WARRANTIES OF BOTH PARTIES........................................29
         7.2      REPRESENTATIONS AND WARRANTIES OF APOLLO..............................................29
         7.3      REPRESENTATION BY LEGAL COUNSEL.......................................................31
         7.4      PRIOR AGREEMENTS......................................................................31
         7.5      APOLLO DISCLAIMER.....................................................................32

8.       TERM AND TERMINATION...........................................................................32

         8.1      TERM AND EXPIRATION...................................................................32
         8.2      TERMINATION BY AHPC...................................................................32
         8.3      TERMINATION BY APOLLO FOR LACK OF DILIGENCE...........................................32
                  8.3.1    FAILURE TO USE COMMERCIALLY REASONABLE EFFORTS...............................33
                  8.3.2    FAILURE TO FILE IND..........................................................33
         8.4      TERMINATION FOR CAUSE.................................................................33
         8.5      EFFECT OF TERMINATION.................................................................34
                  8.5.1    TERMINATION BY AHPC..........................................................34
                  8.5.2    TERMINATION BY APOLLO........................................................34
                  8.5.3    EFFECT OF BANKRUPTCY.........................................................35
         8.6      SURVIVAL OF OBLIGATIONS...............................................................35

9.       INDEMNIFICATION AND INSURANCE..................................................................35

         9.1      INDEMNIFICATION BY AHPC...............................................................35
         9.2      INDEMNIFICATION BY APOLLO.............................................................36
         9.3      CONDITIONS TO INDEMNIFICATION.........................................................36
         9.4      SETTLEMENTS...........................................................................37
         9.5      LIMITATION OF LIABILITY...............................................................37
         9.6      INSURANCE.............................................................................37

10.      CONFIDENTIALITY................................................................................38

         10.1     NONDISCLOSURE OBLIGATION..............................................................38
         10.2     PERMITTED DISCLOSURES.................................................................39
         10.3     RETURN OF INFORMATION.................................................................39
         10.4     DISCLOSURE OF AGREEMENT...............................................................39
         10.5     PUBLICITY.............................................................................39

                                      iii
<Page>

<S>      <C>                                                                                           <C>
11.      MISCELLANEOUS..................................................................................40

         11.1     FORCE MAJEURE.........................................................................40
         11.2     ASSIGNMENT............................................................................40
                  11.2.1   ASSIGNMENT BY APOLLO.........................................................40
                  11.2.2   ASSIGNMENT BY AHPC...........................................................40
                  11.2.3   BINDING NATURE OF ASSIGNMENT.................................................41
         11.3     NO WAIVER.............................................................................41
         11.4     SEVERABILITY..........................................................................41
         11.5     RELATIONSHIP BETWEEN THE PARTIES......................................................41
         11.6     CORRESPONDENCE AND NOTICES............................................................41
                  11.6.1   ORDINARY NOTICES.............................................................41
                  11.6.2   EXTRAORDINARY NOTICES........................................................41
                  11.6.3   ADDRESSES....................................................................42
         11.7     CHOICE OF LAW; DISPUTE RESOLUTION.....................................................42
         11.8     PROVISIONS FOR INSOLVENCY.............................................................44
                  11.8.1   EFFECT ON LICENSES...........................................................44
                  11.8.2   RIGHTS TO INTELLECTUAL PROPERTY..............................................45
                  11.8.3   AHPC'S RIGHTS................................................................45
         11.9     EXPORT CONTROLS.......................................................................46
         11.10    NON-USE OF NAMES......................................................................46
         11.11    ENTIRE AGREEMENT; AMENDMENT...........................................................46
         11.12    HEADINGS..............................................................................46
         11.13    COUNTERPARTS..........................................................................47
         11.14    FURTHER ACTIONS.......................................................................47
</Table>

Exhibit A - Apollo Patent Rights
Exhibit B - Definition of Estrogen Excerpted from U.S. Patent 5,554,601
Exhibit C - Adverse Drug Experience Reporting Procedures

                                       iv
<Page>

                          LICENSE AND OPTION AGREEMENT

         THIS LICENSE AND OPTION AGREEMENT (the "Agreement") is entered into as
of this 8th day of February, 1999, by and between APOLLO BIOPHARMACEUTICS, INC.,
a corporation organized and existing under the laws of the state of Delaware and
having a place of business at One Broadway, Suite 600, Cambridge, Massachusetts
02142 ("Apollo"), and AMERICAN HOME PRODUCTS CORPORATION, acting through its
WYETH-AYERST LABORATORIES DIVISION, a corporation organized and existing under
the laws of the State of Delaware and having a place of business at 555
Lancaster Avenue, St. Davids, Pennsylvania 19087, USA ("AHPC"). Both Apollo and
AHPC are referred to herein individually as a "Party" and collectively as the
"Parties".

         WHEREAS, Apollo has rights to certain patents and/or patent
applications and know-how pertaining to the use of certain estrogen compounds
for the treatment or prevention of neurodegenerative diseases, some of which
rights were obtained pursuant to and are governed by a license granted to Apollo
by [ * CON * ]; and

         WHEREAS, AHPC desires to obtain an exclusive license under such
patents, patent applications and know-how and Apollo desires to grant such a
license to AHPC.

         NOW THEREFORE, in consideration of the foregoing premises and the
mutual promises, covenants and conditions set forth below, the Parties,
intending to be legally bound, hereby agree as follows:

1.       DEFINITIONS.

         1.1      "AFFILIATE(S)" shall mean any corporation, company,
                  partnership, joint venture and/or firm which controls, is
                  controlled by or is under common control with a Party. For
                  purposes of this Section 1.1, "control" shall mean (a) in the
                  case of corporate entities, direct or indirect ownership of at
                  least fifty percent (50%) of the stock or shares having the
                  right to vote for the election of directors, and (b) in the
                  case of non-corporate entities, direct or indirect ownership
                  of at least fifty percent (50%) of the equity interest with
                  the power to direct the management and policies of such
                  non-corporate entities, PROVIDED, HOWEVER, that, for purposes
                  of this Agreement, the term "Affiliate" shall not include any
                  entity with respect to which there is a contractual
                  restriction on the right to elect a majority of the directors
                  or to otherwise direct the management and policies of such
                  entity, until such time as such restrictions are no longer in
                  effect.

         1.2      "APOLLO NCE" shall mean a compound, consisting of an [ * CON *
                  ] and useful or potentially useful as an active ingredient in
                  a pharmaceutical product, the making, using or selling of
                  which would, but for the licenses granted hereunder, infringe
                  a Valid Claim included within the Apollo

<Page>

                  Patent Rights which Valid Claim reads on the composition of
                  matter of such Compound.

         1.3      "APOLLO PATENT RIGHTS" shall mean all patents or patent
                  applications and all divisionals, continuations,
                  continuations-in-part, reissues, renewals, substitutions,
                  extensions, supplementary protection certificates and foreign
                  counterparts thereof, existing as of the Effective Date or
                  filed or issuing during the term of this Agreement which (i)
                  are Controlled by Apollo or its Affiliates and (ii) contain at
                  least one claim which reads on either the composition of
                  matter of any Product or a method of using any Product in the
                  Field. For the sake of clarity, a "method of using any
                  Product" shall not be deemed to include any drug delivery
                  system which may otherwise be encompassed by the Apollo Patent
                  Rights, except to the extent that, with respect to Type D
                  Products and/or Type E Products, on a Product by Product
                  basis, such drug delivery system is the only mechanism or
                  method for delivering such Product to a patient in order to
                  achieve both the desired safety profile and the desired
                  therapeutic or prophylactic effect in the Field. The Apollo
                  Patent Rights existing as of the Effective Date are listed in
                  Exhibit A attached hereto.

         1.4      "COMMERCIALLY REASONABLE EFFORTS" shall mean efforts and
                  resources normally used by a Party for a product owned by it
                  or to which it has rights, which is of similar market
                  potential at a similar stage in its development or product
                  life, taking into account issues of safety and efficacy,
                  product profile, the competitiveness of the marketplace, the
                  proprietary position of the compound or product, the
                  regulatory structure involved, the profitability of the
                  applicable products, and other relevant factors.

         1.5      "CONTROL" OR "CONTROLLED" shall mean with respect to any (i)
                  item of information, including, without limitation, Know-How,
                  or (ii) intellectual property right, the possession (whether
                  by ownership or license) by a Party of the ability to grant to
                  the other Party access and/or a license as provided herein
                  under such item or right without violating the terms of any
                  agreement or other arrangements with any Third Party.

         1.6      "EFFECTIVE DATE" shall mean the next business day following
                  the last to occur of: (i) the delivery to each Party of fully
                  executed counterparts of this Agreement, (ii) a determination
                  made by AHPC's finance committee that a notification of this
                  Agreement is not required to be made under the HSR Act, and
                  (iii) if notification of this Agreement is required to be made
                  under the HSR Act, the expiration or earlier termination of
                  any notice and waiting period under the HSR Act.

         1.7 [ * CON * ]

                                       2
<Page>

         1.8      [ * CON * ]

         1.9      "FIELD" shall mean [ * CON * ].

         1.10     "FIRST COMMERCIAL SALE" shall mean, with respect to any
                  Licensed Product, the first sale of such Licensed Product, for
                  use in the Field, by AHPC, its Affiliates or sublicensees, to
                  a Third Party in any country of the Territory, after such
                  Licensed Product has been granted Regulatory Approval for use
                  in the Field by the competent Regulatory Authorities in such
                  country.

         1.11     [ * CON * ] shall mean that certain Patent License Agreement
                  With Research Component entered into [ * CON * ].

         1.12     "HSR ACT" shall mean the Hart-Scott-Rodino Antitrust
                  Improvements Act of 1976, as amended, and the rules and
                  regulations promulgated thereunder.

         1.13     "INTERIM CLINICAL EVALUATION POINT" or "ICE" shall mean, with
                  respect to any Licensed Product, [ * CON * ].

         1.14     "IND FILING" shall mean the submission by AHPC (with respect
                  to Type A, Type B or Type C Products) or by either Party (with
                  respect to Type D or Type E Products) of an application to the
                  United States Food and Drug Administration ("FDA") to conduct
                  clinical trials with a Product and the allowance by the FDA to
                  commence such studies.

         1.15     "IND TRACK" shall mean the nomination by AHPC, its Affiliates
                  or sublicensees of a Licensed Product for development to IND
                  Filing, according to AHPC's standard internal criteria, an
                  example of which has been provided by AHPC to Apollo on or
                  before the date this Agreement was signed by the Parties.

         1.16     "KNOW-HOW" shall mean all know-how, processes, materials,
                  information, data and analyses including any copyright
                  relating thereto Controlled by Apollo as of the Effective Date
                  or coming into the Control of Apollo during the term of this
                  Agreement relating to estrogen compounds with respect to the
                  Field.

         1.17     "LICENSED PRODUCT(S)" shall mean any Type A Product or Type B
                  Product, and upon AHPC's exercise of the option(s) granted
                  under Section 2.3 hereof and the payment of the applicable
                  option exercise fee, any Type C Product, Type D Product and/or
                  Type E Product, as applicable. For purposes of this Agreement,
                  if two or more Licensed Products contain the same active
                  ingredients they shall be considered to be the same Licensed

                                       3
<Page>

                  Product. Additionally, if one or more of the following
                  products become Licensed Products under this Agreement they
                  shall be considered to be the same Licensed Product for all
                  purposes under this Agreement: [ * CON * ].

         1.18     "MAJOR COUNTRY" shall mean the USA, Canada, France, Germany,
                  U.K., Italy, Japan.

         1.19     "NET SALES" shall mean with respect to a Licensed Product, the
                  gross amount invoiced by AHPC, its Affiliates and/or its
                  sublicensees, on sales or other dispositions of such Licensed
                  Product to unrelated Third Parties, less the following items,
                  provided that such items are actually included in the price
                  charged and do not exceed reasonable and customary amounts in
                  the country in which such sale occurred:

                           (a)      Trade, cash and quantity discounts actually
                                    allowed and taken directly with respect to
                                    such sales;

                           (b)      Excises, sales taxes or other taxes imposed
                                    upon and paid directly with respect to such
                                    sales (excluding national, state or local
                                    taxes based on income);

                           (c)      Amounts repaid or credited by reason of
                                    rejections, defects, recalls or returns or
                                    because of rebates or retroactive price
                                    reduction; and

                           (d)      freight, transportation and insurance.

                  Such amounts shall be determined from the books and records of
                  AHPC, its Affiliates and/or its sublicensees, maintained in
                  accordance with generally accepted accounting principles,
                  consistently applied.

                  If such Licensed Product is sold in bulk (as distinguished
                  from packaged pharmaceutical form) for resale in packaged or
                  finished form, Net Sales shall be calculated by determining
                  the quantity of such Licensed Product in packaged
                  pharmaceutical form that would reasonably be produced from the
                  bulk quantity of such Licensed Product so sold, and by
                  multiplying such quantity by the average price for such
                  Licensed Product in packaged pharmaceutical form during the
                  applicable royalty reporting period. If such Licensed Product
                  is sold, or otherwise commercially disposed of for value
                  (including, without limitation, disposition in connection with
                  the delivery of other products or services), in a transaction
                  that is not a sale for cash to an independent Third Party,
                  then the gross amount invoiced in such transaction shall be
                  deemed to be the gross amount that would have been paid had
                  there been such a sale at the average sale price of such
                  Licensed Product during the applicable royalty reporting
                  period; provided, however, that sale of such

                                       4
<Page>

                  Licensed Product in bulk to a Third Party end user who
                  repackages but does not resell such Licensed Product shall be
                  calculated at the actual transaction price.

                  Net Sales shall not include any consideration received by
                  AHPC, its Affiliates or its licensees or sublicensees in
                  respect of the sale, use or other disposition of such Licensed
                  Product in a country as part of a clinical trial prior to the
                  receipt of all Regulatory Approvals required to commence full
                  commercial sales of such Licensed Product in such country,
                  except sales under "treatment INDS," "named patient sales,"
                  "compassionate use sales," or their equivalents pursuant to
                  which AHPC, its Affiliates or licenses and sublicensees is/are
                  entitled, under applicable laws, regulations and regulatory
                  policies, to recover costs incurred in providing such Licensed
                  Products to the patients.

         1.20     [ * CON * ]

         1.21     [ * CON * ]

         1.22     "OPTION TERM" shall mean the [ * CON * ] ([ * CON * ]) year
                  period commencing on the Effective Date and any extensions of
                  such [ * CON * ] ([ * CON * ]) year period made in accordance
                  with Section 2.4 hereof or as may otherwise be agreed to by
                  the Parties in writing.

         1.23     "PRODUCT" shall mean any pharmaceutical product containing, as
                  an active ingredient, [ * CON * ] or an Apollo NCE.

         1.24     "PRODUCT TYPE" shall mean either all Type A Products, all Type
                  B Products, all Type C Products, all Type D Products or all
                  Type E Products.

         1.25     "REGULATORY APPROVAL" shall mean the technical, medical and
                  scientific licenses, registrations, authorizations and
                  approvals (including, without limitation, approvals of New
                  Drug Applications, supplements and amendments, pre- and post-
                  approvals, pricing and third party reimbursement approvals,
                  and labeling approvals) of any national, supra-national,
                  regional, state or local regulatory agency, department,
                  bureau, commission, council or other governmental entity,
                  necessary for the development, manufacture, distribution,
                  marketing, promotion, offer for sale, use, import, export or
                  sale of Licensed Product(s) in a regulatory jurisdiction.

         1.26     "REGULATORY AUTHORITY" shall mean any mean any national (e.g.,
                  the United States Food and Drug Administration),
                  supra-national (e.g., the European Commission, the Council of
                  the European Union, or the

                                       5
<Page>

                  European Agency for the Evaluation of Medicinal Products),
                  regional, state or local regulatory agency, department,
                  bureau, commission, council or other governmental entity in
                  each country of the Territory involved in the granting of
                  Regulatory Approval for the Licensed Product.

         1.27     "SCIENTIFIC REVIEW COMMITTEE" shall have the meaning set forth
                  in Section 4.5.2 hereof.

         1.28     "START PHASE III" shall mean the first dosing of a patient in
                  a pivotal, registration clinical trial post-Phase II, under a
                  protocol approved by a governmental regulatory agency, to the
                  extent necessary (e.g., the U.S. FDA), in a Major Country.

         1.29     "TERRITORY" shall mean all countries of the world.

         1.30     "THIRD PARTY(IES)" shall mean any person(s) or entity(ies)
                  other than AHPC, Apollo or their respective Affiliates.

         1.31     "TYPE A PRODUCT" shall mean a Product, [ * CON * ], and (iii)
                  the manufacture, use or sale of which, but for the licenses
                  granted hereunder, would infringe a Valid Claim included
                  within the Apollo Patent Rights.

         1.32     "TYPE B PRODUCT" shall mean a Product, [ * CON * ] the
                  manufacture, use or sale of which, but for the licenses
                  granted hereunder, would infringe a Valid Claim included
                  within the Apollo Patent Rights.

         1.33     "TYPE C PRODUCT" shall mean a Product, [ * CON * ]
                  manufacture, use or sale of which, but for the licenses
                  granted hereunder, would infringe a Valid Claim included
                  within the Apollo Patent Rights.

         1.34     "TYPE D PRODUCT" shall mean a Product, [ * CON * ] the
                  manufacture, use or sale of which, but for the licenses
                  granted hereunder, would infringe a Valid Claim included
                  within the Apollo Patent Rights.

         1.35     "TYPE E PRODUCT" shall mean a Product [ * CON * ].

         1.36     [ * CON * ]

         1.37     "VALID CLAIM" shall mean an unexpired claim of an issued and
                  unexpired patent or a claim of a pending patent application,
                  each forming part of the Apollo Patent Rights, which claim has
                  not been (i) declared invalid or unenforceable by a government
                  agency or an order of a court or other tribunal of competent
                  jurisdiction from which no appeal has been or can be taken, or
                  (ii) admitted to be invalid or unenforceable through
                  reexamination, disclaimer or otherwise. Notwithstanding the
                  foregoing, if

                                       6
<Page>

                  a claim of a pending patent application has not issued as a
                  claim of an issued patent within the Apollo Patent Rights,

                           (a)      in the case of United States patent
                                    applications, within [ * CON * ] ([ * CON *
                                    ]) years after the filing date from which
                                    such claim takes priority or

                           (b)      in the case of patent applications filed in
                                    countries other than the United States, [ *
                                    CON * ] ([ * CON * ]) years after the later
                                    of (x) the filing date from which such claim
                                    takes priority or (y) if such national
                                    patent application takes priority from a
                                    patent application filed under the Patent
                                    Cooperation Treaty ("PCT"), the filing date
                                    of such PCT patent application, PROVIDED,
                                    HOWEVER, that with respect to Japanese
                                    patent applications, such [ * CON * ] ([ *
                                    CON * ]) year period shall begin on the date
                                    that the first national patent application
                                    containing such claim is filed in Japan,

                  such pending claim shall cease to be a Valid Claim for
                  purposes of this Agreement unless and until such claim becomes
                  an issued claim of an issued patent within the Apollo Patent
                  Rights.

2.       RIGHTS GRANTED.

         2.1      EXCLUSIVE LICENSE. Apollo hereby grants to AHPC an exclusive
                  (exclusive, even as to Apollo and Apollo's Affiliates) license
                  under the Apollo Patent Rights and to use the Know-How to
                  develop, make, have made, use, market, promote, import, offer
                  for sale, and sell, in the Territory, Licensed Products for
                  use in the Field. With respect to any Apollo Patent Rights
                  which Apollo Controls by virtue of the license granted to
                  Apollo by [ * CON * ], the license granted to AHPC under this
                  Section 2.1 shall be subject only to (i) the non-exclusive
                  license granted to the United States Government, which license
                  is described in Section 2.1 of the [ * CON * ], and (ii) [ *
                  CON * ] reservation of rights, on behalf of the [ * CON * ],
                  to practice under such Apollo Patent Rights for [ * CON * ]
                  own non-commercial research purposes.

         2.2      SUBLICENSES. AHPC shall have the right to grant one or more
                  sublicenses of the license granted to it under Section 2.1
                  hereof to any of its Affiliates or to any Third Party,
                  provided, however, that after granting any such sublicense,
                  AHPC shall provide Apollo with written notice that such
                  sublicense has been granted.

         2.3      GRANT OF OPTIONS.

                                       7
<Page>

                  2.3.1    TYPE C PRODUCTS. Apollo hereby grants to AHPC an
                           exclusive option to obtain an exclusive (exclusive,
                           even as to Apollo and its Affiliates) license under
                           the Apollo Patent Rights and to use the Know-How to
                           develop, make, have made, use, market, promote,
                           import, offer for sale, and sell, in the Territory,
                           Type C Products for use in the Field. In the event
                           that AHPC, in accordance with Section 2.4 hereof,
                           exercises the option provided under this Section
                           2.3.1, Type C Products shall be considered to be
                           Licensed Products for purposes of this Agreement as
                           of the date the applicable option exercise fee is
                           paid in accordance with Section 3.5 hereof.

                  2.3.2    TYPE D PRODUCTS. Apollo hereby grants to AHPC an
                           exclusive option to obtain an exclusive (exclusive,
                           even as to Apollo and its Affiliates) license under
                           the Apollo Patent Rights and to use the Know-How How
                           to develop, make, have made, use, market, promote,
                           import, offer for sale, and sell, in the Territory,
                           Type D Products for use in the Field. In the event
                           that AHPC, in accordance with Section 2.4 hereof,
                           exercises the option provided under this Section
                           2.3.1, Type D Products shall be considered to be
                           Licensed Products for purposes of this Agreement as
                           of the date the applicable option exercise fee is
                           paid in accordance with Section 3.5 hereof.

                  2.3.3    TYPE E PRODUCTS. Apollo hereby grants to AHPC an
                           exclusive option to obtain an exclusive (exclusive,
                           even as to Apollo and its Affiliates) license under
                           the Apollo Patent Rights and to use the Know-How to
                           develop, make, have made, use, market, promote,
                           import, offer for sale, and sell, in the Territory,
                           Type E Products for use in the Field, on a Type E
                           Product by Type E Product basis. In the event that
                           AHPC, in accordance with Section 2.4 hereof,
                           exercises the option provided under this Section
                           2.3.1, with respect to a Type E Product, such Type E
                           Product shall be considered to be a Licensed Product
                           for purposes of this Agreement as of the date the
                           applicable option exercise fee is paid in accordance
                           with Section 3.5 hereof.

         2.4      EXERCISE OF OPTIONS. AHPC may exercise any or all of the
                  options granted to it under Section 2.3.1 hereof by providing
                  to Apollo written notice of AHPC's election to do so prior to
                  the end of the Option Term. AHPC may exercise any or all of
                  the options granted to it under Section 2.3.2 or 2.3.3 hereof
                  by providing to Apollo written notice of AHPC's election to do
                  so no later than forty-five (45) days after AHPC receives the
                  final report at the final meeting of the Scientific Review
                  Committee. After exercising its option with respect to one or
                  more Product Types as set forth

                                       8
<Page>

                  above, AHPC shall pay the applicable option exercise fee(s) as
                  and when required under Section 3.5 hereof, at which time the
                  applicable Product Type(s) shall become Licensed Products
                  under this Agreement. Notwithstanding the foregoing, with
                  respect to Type C Products and Type E Products, AHPC may
                  extend the Option Term by up to [ * CON * ] ([ * CON * ])
                  additional [ * CON * ] ([ * CON * ]) year periods, by (i)
                  providing written notice to Apollo of its intent to so extend
                  the Option Term at least ninety (90) days prior to the
                  expiration of the then current Option Term (as such Option
                  Term may have been extended in accordance with this Section
                  2.4) and (ii) the payment of the appropriate option term
                  extension fee as set forth in Section 3.4 hereof.

         2.5      [ * CON * ]. AHPC acknowledges that a portion of the Apollo
                  Patent Rights and Know-How licensed to AHPC hereunder or
                  pertaining to the options granted to AHPC hereunder are owned
                  by [ * CON * ] and are Controlled by Apollo pursuant to the [
                  * CON * ]. Apollo represents and warrants to AHPC and AHPC
                  acknowledges and agrees that, in the event the [ * CON * ] is
                  terminated for any reason and, at such time, AHPC is not in
                  default of its material obligations under this Agreement such
                  that Apollo would have the right to terminate this Agreement
                  as provided in Article 8 hereof, pursuant to the provisions of
                  the [ * CON * ], any licenses granted or to be granted by
                  Apollo to AHPC hereunder with respect to any Apollo Patent
                  Rights or Know-How which are subject to the [ * CON * ] (i.e.,
                  which are sublicensed, under the [ * CON * ], by Apollo to
                  AHPC) shall become direct licenses between [ * CON * ] and
                  AHPC and, as of such time and thereafter, AHPC shall make all
                  payments due hereunder with respect to such Apollo Patent
                  Rights and Know-How directly to [ * CON * ], which payments,
                  if overdue, shall bear interest until payment is made at the
                  monthly rate of [ * CON * ] percent ([ * CON * ]%) in
                  accordance with Section 5.4 of the [ * CON * ]. Any payments
                  so made to [ * CON * ] shall be deducted from any payments due
                  and payable to Apollo hereunder. Apollo agrees that it will
                  not modify or amend the [ * CON * ] without AHPC's prior
                  written consent, which consent shall not be unreasonably
                  withheld.

         2.6      HSR FILING AND APPROVALS.

                  2.6.1    HSR FILING. To the extent necessary, each of Apollo
                           and AHPC shall file, as soon as practicable after the
                           date this Agreement was signed by each of the
                           Parties, with the Federal Trade Commission (the
                           "FTC") and the Antitrust Division of the United
                           States Department of Justice (the "Antitrust
                           Division") the notification and report form (the
                           "Report") required under the HSR Act with respect to
                           the transactions as contemplated hereby and shall

                                       9
<Page>

                           reasonably cooperate with the other Party to the
                           extent necessary to assist the other Party in the
                           preparation of its Report and to proceed to obtain
                           necessary approvals under the HSR Act, including but
                           not limited to the expiration or earlier termination
                           of any and all applicable waiting periods required by
                           the HSR Act. AHPC shall be responsible for paying any
                           fees required to be paid to any governmental agency
                           in connection with making such filings and each party
                           shall bear its own expenses, including, without
                           limitation, legal fees, incurred in connection with
                           preparing such filings.

                  2.6.2    APOLLO'S AND AHPC'S OBLIGATIONS Each of Apollo and
                           AHPC shall use its good faith efforts to eliminate
                           any concern on the part of any court or government
                           authority regarding the legality of the proposed
                           transaction, including, if required by federal or
                           state antitrust authorities, promptly taking all
                           steps to secure government antitrust clearance,
                           including, without limitation, cooperating in good
                           faith with any government investigation including the
                           prompt production of documents and information
                           demanded by a second request for documents and of
                           witnesses if requested.

                  2.6.3    ADDITIONAL APPROVALS. Apollo and AHPC will cooperate
                           and use respectively all reasonable efforts to make
                           all other registrations, filings and applications, to
                           give all notices and to obtain as soon as practicable
                           all governmental or other consents, transfers,
                           approvals, orders, qualifications authorizations,
                           permits and waivers, if any, and to do all other
                           things necessary or desirable for the consummation of
                           the transactions as contemplated hereby. Neither
                           Party shall be required, however, to divest products
                           or assets or materially change its business if doing
                           so is a condition of obtaining approval under the HSR
                           Act or other governmental approvals of the
                           transactions contemplated by this Agreement.

                  2.6.4    FAILURE TO CLOSE. In the event that on or before [ *
                           CON * ], [ * CON * ], (i) AHPC has not paid to Apollo
                           the initial [ * CON * ] dollar ($[ * CON * ]) license
                           fee as required under Section 3.1 hereof and (ii)
                           AHPC's finance committee fails to make a
                           determination as to whether or not a notification is
                           required to be filed under the HSR Act or, in the
                           event that AHPC's finance committee has determined
                           that a notification must be filed under the HSR Act,
                           AHPC has not filed such notification, then Apollo,
                           prior to the Effective Date, shall have the right to
                           terminate this Agreement by providing AHPC with
                           written notice to such effect. Upon AHPC's receipt of
                           such written notice, this Agreement shall

                                       10
<Page>

                           be null, void and of no effect and neither Party
                           shall have any further rights or obligations
                           hereunder. Notwithstanding the foregoing, the
                           provision of such notice shall have no effect on any
                           other agreements that may exist between the Parties,
                           including, without limitation, that certain
                           confidential disclosure agreement entered into by the
                           Parties on or about [ * CON * ], [ * CON * ].

         2.7      U.S. MANUFACTURE. To the extent that any Licensed Product
                  which (a) is sold in the United States and (b) embodies an
                  invention or is made through the use of an invention which
                  invention is (i) claimed in one or more of the Apollo Patent
                  Rights that Apollo Controls by virtue of the license granted
                  to it by [ * CON * ] under the [ * CON * ] and (ii) a subject
                  invention (as such term is defined in 37 CFR Section 401.2) of
                  a funding agreement between an agency of the United States
                  Government and [ * CON * ], AHPC agrees that it shall
                  substantially manufacture such Licensed Product in the United
                  States, its territories or possessions unless such requirement
                  is waived by the funding agency. Apollo, upon AHPC's request,
                  shall cooperate with AHPC and [ * CON * ] in seeking a waiver
                  of such requirement.

3.       CONSIDERATION.

         3.1      LICENSE FEE. In partial consideration for the rights and
                  licenses granted to AHPC hereunder, AHPC, on the Effective
                  Date, shall pay to Apollo a license fee in the amount of [ *
                  CON * ] dollars ($[ * CON * ]). Additionally, within thirty
                  (30) days after Apollo has provided AHPC with written evidence
                  that a European Patent encompassed within the Apollo Patent
                  Rights and corresponding to United States Patent [ * CON * ]
                  has been granted and published, AHPC shall pay to Apollo the
                  sum of [ * CON * ] dollars ($[ * CON * ]), provided, however,
                  that such amount shall be payable one time only and shall
                  become due and payable only if, in AHPC's reasonable judgment,
                  the claim structure of such European Patent is materially no
                  less comprehensive than the claim structure in United States
                  Patent [ * CON * ].

         3.2      ADDITIONAL FEES - TYPE A PRODUCT. In further consideration for
                  the rights and licenses granted to AHPC hereunder with respect
                  to Type A Product, AHPC shall pay to Apollo additional license
                  fees as follows for each Type A Product developed by AHPC, its
                  Affiliates or sublicensees hereunder for use in the Field,
                  each such payment being due and payable (i) within thirty (30)
                  days after the occurrence of the event triggering such payment
                  hereunder and (ii) only one time with respect to any Type A
                  Product:

                  [ * CON * ]

                                       11
<Page>

         3.3      ADDITIONAL FEES - TYPE B PRODUCTS. In further consideration
                  for the rights and licenses granted to AHPC hereunder with
                  respect to Type B Products, AHPC shall pay to Apollo
                  additional license fees as follows for each Type B Product
                  developed by AHPC, its Affiliates or sublicensees hereunder
                  for use in the Field, each such payment being due and payable
                  (i) within thirty (30) days after the occurrence of the event
                  triggering such payment hereunder and (ii) only one time with
                  respect to any Type B Product:

                           [ * CON * ]

         3.4      OPTION TERM EXTENSION FEES. In the event that AHPC, pursuant
                  to Section 2.4 hereof, elects to extend the Option Term for [
                  * CON * ] ([ * CON * ]) additional [ * CON * ] ([ * CON * ])
                  year period, AHPC shall pay to Apollo an option extension fee
                  in the amount of [ * CON * ] dollars ($[ * CON * ]) which fee
                  shall be due and payable on the [ * CON * ] anniversary of the
                  Effective Date and in the event that AHPC, pursuant to Section
                  2.4 hereof, elects to extend the Option Term for a [ * CON * ]
                  additional [ * CON * ] ([ * CON * ]) year period, AHPC shall
                  also pay to Apollo an additional option extension fee in the
                  amount of [ * CON * ] ($[ * CON * ]), which fee shall be due
                  and payable on the [ * CON * ] anniversary of the Effective
                  Date.

         3.5      OPTION EXERCISE FEE.

                  3.5.1    TYPE C PRODUCTS. In the event that AHPC exercises the
                           option granted to it under Section 2.3.1 hereof, AHPC
                           shall pay to Apollo an option exercise fee in the
                           amount of [ * CON * ] dollars ($[ * CON * ]) which
                           option exercise fee shall be due and payable within
                           ten (10) business days after the later of (i)
                           Apollo's receipt of AHPC's written notice exercising
                           its option under Section 2.3.1 or (ii) if a
                           notification is required to be filed under the HSR
                           Act with respect to AHPC's exercise of the option
                           under Section 2.3.1 hereof, the expiration or early
                           termination of any applicable notice and waiting
                           period under the HSR Act.

                  3.5.2    TYPE D PRODUCTS. In the event that AHPC exercises the
                           option granted to it under Section 2.3.2 hereof, AHPC
                           shall pay to Apollo an option exercise fee in the
                           amount of [ * CON * ] dollars ($[ * CON * ]) which
                           option exercise fee shall be due and payable within
                           ten (10) business days after the later of (i)
                           Apollo's receipt of AHPC's written notice exercising
                           its option under Section 2.3.2 or (ii) if a
                           notification is required to be filed under the HSR
                           Act with respect to AHPC's exercise of the option
                           under Section 2.3.2

                                       12
<Page>

                           hereof, the expiration or early termination of any
                           applicable notice and waiting period under the HSR
                           Act.

                  3.5.3    TYPE E PRODUCTS. In the event that AHPC exercises the
                           option granted to it under Section 2.3.3 hereof, AHPC
                           shall pay to Apollo an option exercise fee in the
                           amount of [ * CON * ] dollars ($[ * CON * ]) which
                           option exercise fee shall be due and payable within
                           ten (10) business days after the later of (i)
                           Apollo's receipt of AHPC's written notice exercising
                           its option under Section 2.3.3 or (ii) if a
                           notification is required to be filed under the HSR
                           Act with respect to AHPC's exercise of the option
                           under Section 2.3.3 hereof, the expiration or early
                           termination of any applicable notice and waiting
                           period under the HSR Act.

         3.6      ADDITIONAL FEES - TYPE C PRODUCTS. In the event that AHPC
                  exercises its option under Section 2.3.1 hereof, then in
                  further consideration for the rights and licenses granted to
                  AHPC hereunder with respect to Type C Products, AHPC shall pay
                  to Apollo additional license fees as follows for each Type C
                  Product developed by AHPC, its Affiliates or sublicensees
                  hereunder for use in the Field, each such payment being due
                  and payable (i) within thirty (30) days after the occurrence
                  of the event triggering such payment hereunder and (ii) only
                  one time with respect to any Type C Product:

                           [ * CON * ]

         3.7      ADDITIONAL FEES - TYPE D PRODUCTS. In the event that AHPC
                  exercises its option under Section 2.3.2 hereof, then in
                  further consideration for the rights and licenses granted to
                  AHPC hereunder with respect to Type D Products, AHPC shall pay
                  to Apollo additional license fees as follows for each Type D
                  Product developed by AHPC, its Affiliates or sublicensees
                  hereunder for use in the Field, each such payment being due
                  and payable (i) within thirty (30) days after the occurrence
                  of the event triggering such payment hereunder and (ii) only
                  one time with respect to any Type D Product:

                           [ * CON * ]

                  Notwithstanding the foregoing, the amounts payable by AHPC
                  under parts (k), (l), (m), (n), (o), and (p) of this Section
                  3.7 shall be payable only for the [ * CON * ] label indication
                  per Type D Product to trigger each such payment, with [ * CON
                  * ] percent ([ * CON * ]%) of the amount specified being
                  payable for the [ * CON * ] such Type D Product label
                  indication to trigger such payment and [ * CON * ] percent ([
                  * CON *

                                       13
<Page>

                  ]%) of the amount specified being payable for the [ * CON * ]
                  such Type D Product label indication to trigger such payment.

         3.8      ADDITIONAL FEES - TYPE E PRODUCTS. In the event that AHPC
                  exercises its option under Section 2.3.3 hereof, then in
                  further consideration for the rights and licenses granted to
                  AHPC hereunder with respect to Type E Products, AHPC shall pay
                  to Apollo additional license fees as follows for each Type E
                  Product developed by AHPC, its Affiliates or sublicensees
                  hereunder for use in the Field, each such payment being due
                  and payable (i) within thirty (30) days after the occurrence
                  of the event triggering such payment hereunder and (ii) only
                  one time with respect to any Type E Product:

                           [ * CON * ]

                  Notwithstanding the foregoing, the amounts payable by AHPC
                  under parts (k), (l), (m), (n), (o), and (p) of this Section
                  3.8 shall be payable only for the [ * CON * ] label
                  indications per Type E Product to trigger each such payment,
                  with [ * CON * ] percent ([ * CON * ]%) of the amount
                  specified being payable for the [ * CON * ] such Type E
                  Product label indication to trigger such payment and [ * CON *
                  ] percent ([ * CON * ]%) of the amount specified being payable
                  for the [ * CON * ] such Type E Product label indication to
                  trigger such payment.

         3.9      ROYALTIES.

                  3.9.1    ROYALTY RATES -- TYPE A PRODUCTS. In further
                           consideration for the licenses and other rights
                           granted to AHPC hereunder with respect to Type A
                           Products, AHPC shall pay to Apollo royalties, with
                           respect to each Type A Product sold by AHPC, its
                           Affiliates or sublicensees, as follows:

                                    [ * CON * ]

                           Each such quarterly payment shall be made at the time
                           set forth in Section 3.10.1 hereof, with the first
                           such quarterly payment being due and payable after
                           the end of the Calendar Quarter in which such First
                           Commercial Sale was made. Notwithstanding the
                           foregoing, in the event that, during any Calendar
                           Quarter, AHPC, its Affiliates, or sublicensees sell a
                           Type A Product in one or more countries of the
                           Territory where there is not a Valid Claim covering
                           the use of such Type A product in the Field, the
                           royalty payable with respect to such Calendar Quarter
                           under this Section 3.9.1 shall be adjusted by
                           multiplying the amount set forth in Section 3.9.1(a),
                           3.9.1(b) or 3.9.1(c), as applicable, by a factor
                           equal to [ * CON * ],

                                       14
<Page>

                           where [ * CON * ] is the sum of AHPC's, its
                           Affiliates' and its sublicensees' Net Sales of Type A
                           Products in such countries during such Calendar
                           Quarter and [ * CON * ] is the sum of AHPC's, its
                           Affiliates' and its sublicensees' worldwide Net Sales
                           of Type A Products during such Calendar Quarter.

                  3.9.2    ROYALTY RATES -- TYPE B PRODUCTS. In further
                           consideration for the licenses and other rights
                           granted to AHPC hereunder with respect to Type B
                           Products, AHPC shall pay to Apollo royalties in the
                           amount of [ * CON * ] ([ * CON * ]%) of the Net Sales
                           of Type B Products sold for use in the Field. In the
                           event that AHPC, its Affiliates or sublicensees has
                           been granted Regulatory Approval in any country of
                           the Territory to market a Type B Product for use both
                           in the Field and in at least one additional
                           therapeutic or prophylactic indication, [ * CON * ],
                           AHPC and Apollo shall meet to discuss the methods
                           proposed to be used by AHPC to determine what
                           proportion of such Type B Product sold in such
                           country(ies) was sold for use in the Field for
                           purposes of calculating the royalty payable
                           hereunder.

                  3.9.3    ROYALTY RATES -- TYPE C PRODUCTS. If AHPC exercises
                           the option granted to it under Section 2.3.1 hereof,
                           then in further consideration for the licenses and
                           other rights granted to AHPC hereunder with respect
                           to Type C Products, AHPC shall pay to Apollo
                           royalties in the amount of [ * CON * ] ([ * CON * ]%)
                           of the Net Sales of Type C Products sold for use in
                           the Field. In the event that AHPC, its Affiliates or
                           sublicensees has been granted Regulatory Approval in
                           any country of the Territory to market a Type C
                           Product for use both in the Field and in at least one
                           additional therapeutic or prophylactic indication [ *
                           CON * ] AHPC and Apollo shall meet to discuss the
                           methods proposed to be used by AHPC to determine what
                           proportion of such Type C Product sold in such
                           country(ies) was sold for use in the Field for
                           purposes of calculating the royalty payable
                           hereunder.

                  3.9.4    ROYALTY RATES -- TYPE D PRODUCTS. If AHPC exercises
                           the option granted to it under Section 2.3.2 hereof,
                           then in further consideration for the licenses and
                           other rights granted to AHPC hereunder with respect
                           to Type D Products, AHPC shall pay to Apollo
                           royalties in the amount of [ * CON * ] ([ * CON * ]%)
                           of the Net Sales of Type D Products sold for use in
                           the Field. In the event that AHPC, its Affiliates or
                           sublicensees has been granted Regulatory Approval in
                           a Major Country to market a Type D Product for use
                           both in the Field and in at least one additional
                           therapeutic or prophylactic indication [ * CON * ]
                           AHPC and

                                       15
<Page>

                           Apollo shall meet to discuss the methods proposed to
                           be used by AHPC to determine what proportion of such
                           Type D Product sold in such country(ies) was sold for
                           use in the Field for purposes of calculating the
                           royalty payable hereunder.

                  3.9.5    ROYALTY RATES -- TYPE E PRODUCTS. If AHPC exercises
                           the option granted to it under Section 2.3.3 hereof,
                           then in further consideration for the licenses and
                           other rights granted to AHPC hereunder with respect
                           to such Type E Products, AHPC shall pay to Apollo
                           royalties in the amount of [ * CON * ].

                  3.9.6    TERM AND SCOPE OF ROYALTY OBLIGATIONS. Royalties on
                           each Licensed Product sold by or on behalf of AHPC,
                           its Affiliates or their respective sublicensees, at
                           the rates set forth in this Section 3.9 shall
                           continue on a Licensed Product by Licensed Product
                           and a country-by-country basis until the expiration
                           of the Term of this Agreement in such country with
                           respect to such Licensed Product as provided in
                           Section 8.1 hereof. No royalties shall be due upon
                           the sale or other transfer among AHPC, its Affiliates
                           or sublicensees, but in such cases the royalty shall
                           be due and calculated upon AHPC's or its Affiliates'
                           or its sublicensees' Net Sales to the first
                           independent Third Party.

                  3.9.7    THIRD PARTY LICENSES. In the event that AHPC
                           determines, based on the advice of outside patent
                           counsel selected by AHPC and reasonably acceptable to
                           Apollo, that patent licenses from Third Parties
                           (hereinafter "Third Party Patent Licenses"), are
                           required by AHPC, its Affiliates and sublicensees in
                           order to develop, make, have made, import, export,
                           use, distribute, promote, market, offer for sale or
                           sell any Licensed Product in the Field, PROVIDED,
                           HOWEVER, that in the case of Type A Products, Type B
                           Products, Type C Products or Type D Products, such
                           Third Party Patents claim the use of such Licensed
                           Products in the Field then the royalty rates set
                           forth in this Section 3.9 shall be adjusted such that
                           the royalty which AHPC is obligated to pay Apollo
                           hereunder for such Licensed Product shall be reduced
                           by [ * CON * ] cents ($[ * CON * ]) for each [ * CON
                           * ] in royalties which AHPC is obligated to pay Third
                           Parties under Third Party Patent Licenses PROVIDED,
                           HOWEVER, that the royalty payable by AHPC hereunder
                           shall not be reduced, pursuant to this Section 3.9.7,
                           to less than [ * CON * ] percent ([ * CON * ]%) of
                           the royalty that would have otherwise been due to
                           Apollo hereunder in any Calendar Quarter. For
                           purposes of this Section 3.9.7, patent claims reading
                           on (i) [ * CON * ] shall not be considered to be a
                           claim on the use of such Licensed Products in the
                           Field. To the extent that AHPC is able to

                                       16
<Page>

                           do so without foregoing any attorney-client privilege
                           that AHPC may have with respect to the advice
                           provided by such outside patent counsel, AHPC, upon
                           Apollo's request, shall communicate or shall
                           authorize such outside patent counsel to communicate
                           the substance of such advice to Apollo or Apollo's
                           outside patent counsel, PROVIDED, HOWEVER, that AHPC
                           shall have no obligation whatsoever to provide Apollo
                           with a copy of any written opinion of such outside
                           patent counsel or other written communication between
                           AHPC and such outside patent counsel.

         3.10     REPORTS AND PAYMENT OF ROYALTY.

                  3.10.1   ROYALTIES PAID QUARTERLY. Within sixty (60) calendar
                           days following the close of each Calendar Quarter,
                           following the First Commercial Sale of a Licensed
                           Product, AHPC shall furnish to Apollo a written
                           report for the Calendar Quarter showing, on a Product
                           Type by Product Type basis and, only to the extent
                           necessary to calculate any reductions in royalties
                           made pursuant to Sections 3.9.1 or 6.4.4 hereof, on a
                           country-by-country basis, (i) the Net Sales of Type B
                           Products and, if the applicable options under Section
                           2.3 have been exercised, Type C Products, Type D
                           Products and Type E Products sold by AHPC, its
                           Affiliates and its sublicensees in the Territory
                           during such Calendar Quarter, and (ii) the royalties
                           payable under this Agreement for such Calendar
                           Quarter. Simultaneously with the submission of the
                           written report, AHPC shall pay to Apollo, for the
                           account of AHPC or the applicable Affiliate or
                           sublicensee, as the case may be, a sum equal to the
                           aggregate royalty due for such Calendar Quarter
                           calculated in accordance with this Agreement
                           (reconciled for any previous overpayments,
                           underpayments or credits).

                  3.10.2   METHOD OF PAYMENT. Payments to be made by AHPC to
                           Apollo under this Agreement shall be paid at AHPC's
                           option, either by bank wire transfer in immediately
                           available funds to such bank account as is designated
                           in writing by Apollo from time to time or by check in
                           immediately available funds. Royalty payments shall
                           be made in United States dollars.

         3.11     MAINTENANCE OF RECORDS; AUDITS.

                  3.11.1   RECORD KEEPING BY AHPC. AHPC shall keep and shall
                           cause its Affiliates and sublicensees to keep
                           accurate books and accounts of record in connection
                           with the sale of the Licensed Products in sufficient
                           detail to permit accurate determination of all
                           figures necessary for verification of payments
                           required to be paid

                                       17
<Page>

                           hereunder. AHPC and its Affiliates and sublicensees
                           shall maintain such records for a period of at least
                           three (3) years after the end of the year in which
                           they were generated.

                  3.11.2   AUDIT BY APOLLO. Upon forty-five (45) days prior
                           written notice from Apollo, AHPC shall permit an
                           independent certified public accounting firm of
                           nationally recognized standing selected by Apollo and
                           reasonably acceptable to AHPC, to examine, at
                           Apollo's sole expense, the relevant books and records
                           of AHPC and its Affiliates as may be reasonably
                           necessary to verify the accuracy of the royalty
                           reports and royalties paid hereunder. The examination
                           shall be limited to pertinent books and records for
                           any year ending not more than thirty-six (36) months
                           prior to the date of such request. An examination
                           under this Section 3.11.2 shall not occur more than
                           once in any calendar year. Such examination shall be
                           conducted after reasonable prior written notice to
                           AHPC and during ordinary business hours. The
                           accounting firm shall provide both Apollo and AHPC a
                           written report disclosing only whether the royalty
                           reports are correct or incorrect and the specific
                           details concerning any discrepancies. No other
                           information shall be provided to Apollo. All such
                           accounting firms shall sign a confidentiality
                           agreement (in form and substance reasonably
                           acceptable to AHPC) as to any of AHPC's or its
                           Affiliate's confidential information which they are
                           provided, or to which they have access, while
                           conducting any audit pursuant to this Section 3.11.2.
                           Upon the expiration of sixty (60) months following
                           the end of any year, the calculation of royalties
                           payable with respect to such year shall be binding
                           and conclusive upon Apollo and AHPC and its
                           Affiliates and sublicensees shall be released from
                           any liability or accountability with respect to
                           royalties for such year.

                  3.11.3   UNDERPAYMENTS/OVERPAYMENTS. If such independent
                           accountant correctly concludes that additional
                           royalties were owed during such period, AHPC shall
                           pay the additional royalties, together with any
                           interest that may be due thereon as provided in
                           Section 3.14, within thirty (30) days of the date
                           AHPC receives such accountant's written report so
                           concluding. If such underpayment exceeds [ * CON * ]
                           percent ([ * CON * ]%) of the royalty correctly due
                           Apollo then the reasonable fees charged by such
                           accountant for the work associated with the
                           underpayment audit shall be paid by AHPC. Any
                           overpayments by AHPC will be promptly refunded by
                           Apollo to AHPC together with interest thereon at the
                           rate provided in Section 3.14.

                                       18
<Page>

                  3.11.4   RECORD KEEPING BY SUBLICENSEE. AHPC shall include in
                           each sublicense granted by it pursuant to this
                           Agreement a provision requiring the sublicensee to
                           make reports to AHPC, to keep and maintain records of
                           sales made pursuant to such sublicense and to grant
                           access to such records by Apollo's independent
                           certified public accounting to the same extend
                           required of AHPC under this Agreement.

                  3.11.5   CONFIDENTIALITY. Apollo shall treat all financial
                           information subject to review under this Section
                           3.11, or under any sublicense agreement, in
                           accordance with the provisions of Article 10 hereof,
                           except when it is necessary to reveal such
                           information in order to enforce its rights under this
                           Agreement.

         3.12     TAXES AND WITHHOLDING. All taxes, assessments and fees of any
                  nature levied or incurred on account of any payments from AHPC
                  to Apollo accruing under this Agreement, by national, state or
                  local governments, will be assumed and paid by AHPC, except
                  taxes levied thereon as income to Apollo and if such taxes are
                  required to be withheld by AHPC they will be deducted from
                  payments due to Apollo and will be timely paid by AHPC to the
                  proper taxing authority for the account of Apollo, a receipt
                  or other proof of payment therefor secured and sent to Apollo
                  as soon as practicable.

         3.13     FOREIGN EXCHANGE. For the purpose of computing Net Sales for
                  Licensed Products sold in a currency other than United States
                  Dollars, such currency shall be converted into United States
                  Dollars in accordance with AHPC's customary and usual
                  translation procedures, consistently applied.

         3.14     INTEREST. Any payment that is more than [ * CON * ] ([ * CON *
                  ]) days past due shall thereafter be subject to interest at an
                  annual percentage rate of [ * CON * ] ([ * CON * ]) [ * CON *
                  ] on the date that such interest begins to accrue.

4.       PRODUCT DEVELOPMENT AND COMMERCIALIZATION.

         4.1      DEVELOPMENT AND REGISTRATION OF LICENSED PRODUCTS.

                  4.1.1    DILIGENCE OBLIGATION. AHPC shall use its Commercially
                           Reasonable Efforts to develop and apply for
                           Regulatory Approval for at least one Licensed Product
                           in the Field in each of the Major Countries,
                           PROVIDED, HOWEVER, that the decision of whether or
                           not to initiate or continue the development of any
                           particular Product or Product Type for use in the
                           Field shall be in AHPC's sole discretion.

                                       19
<Page>

                  4.1.2    TYPE D PRODUCTS. If AHPC exercises its option under
                           Section 2.3.2 hereof, AHPC, notwithstanding its
                           obligations as set forth in Section 4.1.1 hereof,
                           which obligations may be met by using its
                           Commercially Reasonable Efforts to develop and apply
                           for Regulatory Approval for at least one Type D
                           Product in the Field in each of the Major Countries,
                           also shall use its Commercially Reasonable Efforts to
                           file an IND with respect to at least one Type D
                           Product prior to the later to occur of (i) the [ *
                           CON * ] anniversary of the Effective Date or (ii) [ *
                           CON * ] ([ * CON * ]) year after the payment of the
                           option exercise fee required under Section 3.5.2
                           hereof.

                  4.1.3    TYPE E PRODUCTS. If AHPC exercises its option under
                           Section 2.3.3 hereof for one or more Type E Products,
                           AHPC, notwithstanding its obligations as set forth in
                           Section 4.1.1 hereof, which obligations may be met by
                           using its Commercially Reasonable Efforts to develop
                           and apply for Regulatory Approval for at least one
                           Type E Product in the Field in each of the Major
                           Countries, also shall use its Commercially Reasonable
                           Efforts to file an IND with respect to at least one
                           Type E Product prior to the later to occur of (i) the
                           [ * CON * ] anniversary of the Effective Date or (ii)
                           [ * CON * ] ([ * CON * ]) year after the payment of
                           the option exercise fee required under Section 3.5.3
                           hereof.

         4.2      EXTENSION OF TIME. Upon AHPC's request and subject to Apollo's
                  consent, such consent not to be unreasonably withheld or
                  delayed, the time periods specified in Sections 4.1.3, 4.1.4
                  and 4.1.5 for filing an IND for the applicable Licensed
                  Product shall be extended by the period of time specified in
                  AHPC's request, provided that AHPC is able to reasonably
                  demonstrate that the reason the filing of the applicable IND
                  was not accomplished within the time period specified in
                  Section 4.1.3, 4.1.4 or 4.1.5, as applicable, was not due to a
                  lack of Commercially Reasonable Efforts on AHPC's part and
                  that, due to circumstances beyond AHPC's reasonable control,
                  such additional time period is necessary.

         4.3      COMMERCIALIZATION OF LICENSED PRODUCTS. After obtaining
                  Regulatory Approval for a Licensed Product, other than a Type
                  B Product, in a Major Country, AHPC shall use its Commercially
                  Reasonable Efforts to market and sell such Licensed Product in
                  such Major Country.

         4.4      STATUS REPORTS. Within sixty (60) days after each December 31
                  and June 30 during the term of this Agreement AHPC shall
                  provide Apollo with a report summarizing the development
                  decisions made with respect to Licensed Products during the
                  period covered by the report and the then

                                       20
<Page>

                  current status of its Licensed Product development activities.
                  Such summary shall include estimated time lines for planned
                  future development activities for Licensed Products then under
                  development. Apollo acknowledges that such reports are being
                  provided at Apollo's request for informational purposes only
                  and any information or statements made therein shall not be
                  construed as imposing upon AHPC any specific obligations with
                  respect to the development of any particular Licensed Product
                  Apollo shall treat all such reports as Information in
                  accordance with Article 10 hereof. Notwithstanding the
                  foregoing, the first such report shall be due within sixty
                  (60) days after June 30, 1999.

         4.5      APOLLO DEVELOPMENT AND REPORTING OBLIGATIONS.

                  4.5.1    DEVELOPMENT. As a fundamental condition of, and in
                           consideration of the payments to Apollo contemplated
                           by this Agreement, Apollo agrees, throughout the
                           Option Term, to use its Commercially Reasonable
                           Efforts and to apply such of its technical and
                           financial resources as are reasonably necessary to
                           establish and maintain one or more programs for the
                           discovery and/or development of Type E Products. Such
                           resources shall include, without limitation, internal
                           and/or external programs with scientific experts in
                           steroid chemistry and related analytical methods as
                           well as programs for specific structure/function
                           analysis specific to applications in the Field.

                  4.5.2    SCIENTIFIC REVIEW COMMITTEE; REPORTS. Promptly after
                           the Effective Date, the Parties will establish a
                           Scientific Review Committee (the "Committee")
                           consisting of two (2) representatives from AHPC and
                           two (2) representatives from Apollo. The chairperson
                           of such Committee shall be one of the AHPC
                           representatives. Either Party may replace any of its
                           representatives at any time upon written notice to
                           the other Party. The Committee shall meet in person
                           to review new Know-How Controlled by Apollo or its
                           Affiliates which relates to Type D Products and/or
                           Type E Products or the active ingredients thereof.
                           Such meetings shall occur at least two (2) times per
                           year (or more or less frequently as the Parties may
                           mutually agree in writing) during the Option Term and
                           a final meeting shall be held no later than thirty
                           (30) days after the end of the Option Term. During
                           such final meeting Apollo shall present and submit to
                           the Committee and AHPC a final written report
                           describing the Know-How and Apollo Patent Rights
                           Controlled by Apollo or its Affiliates which relates
                           to Type D Products and/or Type E Products or the
                           active ingredients thereof. The time and date of each
                           such meeting shall be set by mutual agreement of the
                           Committee members and the

                                       21
<Page>

                           location of such meetings shall alternate between the
                           facilities of Apollo and AHPC with the first such
                           meeting being held at one of AHPC's facilities. Each
                           party shall be responsible for the expenses incurred
                           by its representatives in attending such Committee
                           meetings.

5.       REGULATORY MATTERS.

         5.1      REGULATORY FILINGS. Subject to the obligations set forth in
                  Section 4.1 hereof, AHPC shall, in its own name and at its own
                  expense, prepare and file all INDs and all applications for
                  Regulatory Approval of Licensed Products for use in the Field
                  in those countries of the Territory where AHPC, in its sole
                  discretion, deems it commercially reasonable to do so. AHPC
                  agrees to provide Apollo with copies of correspondence with
                  the applicable Regulatory Authorities which correspondence
                  concerns the INDs permitting the study, in humans, of Type E
                  Products and applications for Regulatory Approval of Type E
                  Products. AHPC shall have no obligation to disclose to Apollo
                  any INDs, applications for Regulatory Approval or related
                  correspondence that pertains to any other Product Type.

         5.2      ADVERSE EVENT REPORTING. AHPC shall be responsible for
                  reporting all adverse events associated with each Licensed
                  Product to the appropriate Regulatory Authorities in
                  accordance with applicable laws, rules and regulations.
                  Additionally, in the event Apollo receives information
                  regarding adverse drug experiences related to the use of any
                  Licensed Product, Apollo shall promptly provide AHPC with such
                  information in accordance with the Adverse Drug Experience
                  Reporting Procedures (as may be amended from time to time upon
                  mutual agreement) set forth in Exhibit C. Further, AHPC shall
                  provide Apollo with copies of any adverse drug experience
                  reports concerning Type E Products which reports have been
                  submitted by AHPC to the applicable Regulatory Authorities.

6.       INTELLECTUAL PROPERTY.

         6.1      FILING, PROSECUTION AND MAINTENANCE OF APOLLO PATENT RIGHTS.
                  Apollo agrees to use its Commercially Reasonable Efforts to
                  file, prosecute and maintain in the Territory, upon
                  appropriate consultation with AHPC, the Apollo Patent Rights
                  Controlled in whole or in part by Apollo and licensed to AHPC
                  under this Agreement. Apollo shall give AHPC an opportunity to
                  review the text of the applications for such Apollo Patent
                  Rights before filing, shall consult with AHPC with respect
                  thereto, and shall supply AHPC with a copy of the applications
                  as filed, together with notice of its filing date and serial
                  number. Apollo shall keep AHPC advised of the status of the
                  actual and prospective patent filings (including,

                                       22
<Page>

                  without limitation, the grant of any such Apollo Patent
                  Rights), and shall provide advance copies of any substantive
                  papers related to the filing, prosecution and maintenance of
                  such patent filings. AHPC acknowledges that, pursuant to the
                  Florida License, all final decisions with respect to the
                  prosecution of any of the Apollo Patent Rights which are owned
                  by [ * CON * ] and Controlled by Apollo by virtue of the
                  license granted to Apollo by [ * CON * ] under the [ * CON * ]
                  shall be reserved to [ * CON * ]. Notwithstanding the
                  foregoing, Apollo shall not be required to disclose to AHPC
                  any such application which claims the composition or use of a
                  Type E Product but does not claim or describe the composition
                  or use of any other Product Type, until after the first patent
                  application (including, without limitation, a provisional
                  patent application) claiming the composition or use of such
                  Type E Product has been filed. AHPC shall reimburse Apollo for
                  the reasonable out-of-pocket expenses incurred by Apollo after
                  the Effective Date in filing, prosecuting and maintaining the
                  Apollo Patent Rights owned in whole or in part by Apollo and
                  licensed to AHPC under this Agreement, PROVIDED, HOWEVER, that
                  AHPC, in its sole discretion, may elect not to pay for the
                  defense of an interference or other legal action relating to
                  such Patent Rights in the Territory. Within thirty (30) days
                  after the end of each calendar quarter Apollo shall invoice
                  AHPC for any reimbursable expenses paid by Apollo during such
                  calendar quarter. AHPC shall reimburse Apollo for such
                  expenses within thirty (30) days of AHPC's receipt of such
                  invoice.

         6.2      OPTION OF AHPC TO PROSECUTE AND MAINTAIN APOLLO PATENT RIGHTS.
                  Apollo shall give one hundred and eighty (180) days written
                  notice to AHPC of any desire to cease prosecution and/or
                  maintenance of a particular Apollo Patent Right and, in such
                  case, shall permit AHPC, at AHPC's sole discretion, to
                  continue prosecution or maintenance of such Apollo Patent
                  Right at AHPC's own expense. If AHPC elects to continue
                  prosecution or maintenance of such Apollo Patent Right, Apollo
                  shall execute such documents and perform such acts, at
                  Apollo's expense, as may be reasonably necessary to effect an
                  assignment to AHPC of such Apollo Patent Rights which are
                  owned by Apollo. Any such assignment shall be completed in a
                  timely manner so as to allow AHPC to continue such prosecution
                  or maintenance. Any patents or patent applications so assigned
                  shall thereafter not be considered Apollo Patent Rights for
                  any purpose under this Agreement.

         6.3      ENFORCEMENT OF APOLLO PATENT RIGHTS.

                  6.3.1    NOTICE AND DISCONTINUANCE OF INFRINGEMENT. In the
                           event that either Apollo or AHPC becomes aware of any
                           infringement within the Territory of any Valid Claim
                           within the Apollo Patent Rights, it

                                       23
<Page>

                           will notify the other Party in writing to that
                           effect. Any such notice shall include evidence to
                           support an allegation of infringement by such Third
                           Party. Apollo shall have the right, but not the
                           obligation to take any such action which it
                           reasonably deems necessary to obtain a discontinuance
                           of such infringement or to bring suit against the
                           Third Party infringer. AHPC shall have the right,
                           prior to commencement of the trial, suit or action
                           brought by Apollo, to join any such suit or action,
                           in which event the expenses of any such suit shall be
                           shared equally by Apollo and AHPC. In no event shall
                           Apollo enter into any settlement, consent judgment or
                           other voluntary final disposition of such suit which
                           would adversely affect AHPC's rights under this
                           Agreement in any way without first obtaining AHPC's
                           written consent to do so, which consent shall not be
                           unreasonably withheld. Additionally, in the event
                           that AHPC has joined in the action and shared in the
                           costs thereof as set forth above, no settlement,
                           consent judgment or other voluntary final disposition
                           of the suit may be entered into without the consent
                           of AHPC. In the event that AHPC has not joined the
                           suit or action, AHPC will reasonably cooperate with
                           Apollo in any such suit or action and shall have the
                           right to consult with Apollo and be represented by
                           its own counsel at its own expense. [ * CON * ] It is
                           understood that Apollo may share its portion of
                           expenses and any recovery with [ * CON * ] pursuant
                           to the [ * CON * ].

                  6.3.2    CONTINUANCE OF INFRINGEMENT. If the alleged
                           infringement of the Apollo Patent Rights is occurring
                           within the Field and, within six (6) months after
                           AHPC has provided Apollo with the notice specified in
                           the first sentence of Section 6.2.1, Apollo has not
                           overcome the allegation of infringement, obtained a
                           discontinuance of such infringement or filed suit
                           against such Third Party infringer, then AHPC shall
                           have the right, but not the obligation, to bring suit
                           against such Third Party infringer under the Apollo
                           Patent Rights and join Apollo as a party plaintiff.
                           Apollo will cooperate with AHPC in any suit for
                           infringement of an Apollo Patent Right brought by
                           AHPC against a Third Party, and shall have the right
                           to consult with AHPC and to participate in and be
                           represented by independent counsel in such litigation
                           at its own expense. If the Apollo Patent Rights that
                           are allegedly being infringed are Controlled by
                           Apollo by virtue of the license granted to Apollo by
                           [ * CON * ] under the [ * CON * ], AHPC shall
                           not enter into any settlement, consent judgment or
                           other voluntary final disposition of such suit
                           without first obtaining [ * CON * ] written consent
                           to do so, which consent, pursuant to the [

                                       24
<Page>

                           * CON * ], shall not be unreasonably withheld. Apollo
                           shall cooperate with AHPC in obtaining such consent.
                           [ * CON * ]

         6.4      INFRINGEMENT OF THIRD PARTY PATENTS; THIRD PARTY LICENSES.

                  6.4.1    COURSE OF ACTION. In the event that AHPC's, its
                           Affiliates' or its sublicensees' making, having made,
                           importing, exporting, using, distributing, marketing,
                           promoting, offering for sale or selling Licensed
                           Products in the Field infringes, will infringe or is
                           alleged by a Third Party to infringe a Third Party's
                           patent (PROVIDED, HOWEVER, that in the case of Type A
                           Products, Type B Products, Type C Products and Type D
                           Products, such Third Party patent claims the use of
                           such Licensed Product in the Field) the Party
                           becoming aware of same shall promptly notify the
                           other.

                  6.4.2    AHPC OPTION TO NEGOTIATE. AHPC shall in the first
                           instance have the right to negotiate with said Third
                           Party for a suitable license or assignment PROVIDED,
                           HOWEVER, that AHPC shall enter into no such agreement
                           unless it has first obtained Apollo's approval (which
                           approval shall not be unreasonably withheld or
                           delayed) of any royalties or payments which are to be
                           deducted from payments to be made to Apollo
                           hereunder. In the event that such negotiation results
                           in a consummated agreement, then any lump sum payment
                           made thereunder shall be paid by AHPC and [ * CON * ]
                           percent ([ * CON * ]%) of such payment shall offset
                           any royalties due Apollo hereunder, but only to the
                           extent of reducing royalties due Apollo with respect
                           to the Product Type(s) and country(ies) affected by [
                           * CON * ] percent ([ * CON * ]%) in any Calendar
                           Quarter. Any unused amounts not so offset can be
                           carried over to subsequent quarters.

                  6.4.3    APOLLO OPTION TO NEGOTIATE. Should AHPC fail to
                           consummate an agreement with said Third Party within
                           one (1) year of initiating negotiations, then Apollo
                           shall have the right to negotiate with said Third
                           Party for a suitable license or assignment. In the
                           event that such negotiation results in a consummated
                           agreement, then any lump sum payments made thereafter
                           shall be paid by Apollo. Should such agreement
                           require the payment of royalties, AHPC shall continue
                           to pay the royalties due Apollo hereunder and Apollo
                           shall pay any royalties due said Third Party on
                           AHPC's behalf.

                  6.4.4    THIRD PARTY INFRINGEMENT SUIT. In the event that a
                           Third Party sues AHPC alleging that AHPC's, its
                           Affiliates' or its sublicensees' making, having made,
                           importing, exporting, using,

                                       25
<Page>

                           distributing, marketing, promoting, offering for sale
                           or selling any Licensed Product in the Field
                           infringes or will infringe said Third Party's patent
                           (PROVIDED, HOWEVER, that in the case of Type A
                           Products, Type B Products, Type C Products and/or
                           Type D Products, such Third Party patent claims the
                           use of such Licensed Products in the Field), then
                           AHPC may, in its sole discretion, elect to defend
                           such suit and, during the period in which such suit
                           is pending, AHPC shall have the right to apply [ *
                           CON * ] the royalties due Apollo, which royalties are
                           based on the allegedly infringing sales of Licensed
                           Product(s) against its litigation expenses, including
                           settlement costs and royalties paid in settlement of
                           any such suit, PROVIDED, HOWEVER, that in the event
                           that a Type A Product is the subject of such an
                           infringement suit, the portion of the royalties
                           payable under Section 3.9.1 hereof which shall be
                           attributable to the allegedly infringing sales of
                           such Licensed Product for purposes of calculating the
                           amount of royalties payable in any Calendar Quarter
                           that may be attributed to litigation expenses under
                           this Section 6.4.4. shall be calculated by
                           multiplying the royalty amount set forth in Section
                           3.9.1(a), 3.9.1(b) or 3.9.1(c), as applicable, by a
                           factor equal to [ * CON * ], where [ * CON * ] is the
                           sum of AHPC's, its Affiliates' and its sublicensees'
                           Net Sales made during such Calendar Quarter of Type A
                           Products in the country(ies) where the infringement
                           is alleged to be taking place and [ * CON * ] is the
                           sum of AHPC's, its Affiliates' and its sublicensees'
                           worldwide Net Sales of Type A Products during such
                           Calendar Quarter. Upon AHPC's request and in
                           connection with AHPC's defense of any such Third
                           Party infringement suit, Apollo shall provide
                           reasonable assistance to AHPC for such defense. For
                           purposes of this Section 6.4.4, patent claims reading
                           on (i) the composition of Type A Products, Type B
                           Products, Type C Products and/or Type D Products,
                           (ii) processes for manufacturing such Licensed
                           Products and/or drug delivery systems used by AHPC in
                           connection with such Licensed Products shall not be
                           considered not be considered to be a claim on the use
                           of such Licensed Products in the Field. Should AHPC
                           recovery any damages, by way of settlement or
                           otherwise, in connection with any counterclaim made
                           by it in any such Third Party infringement suit, such
                           recovery shall be used first to reimburse AHPC for
                           the costs and expenses it incurred in defending such
                           Third Party infringement suit (including, without
                           limitation, the costs and expenses incurred in
                           pursuing any counterclaims in such suit) and second
                           to reimburse Apollo for any royalties withheld
                           pursuant to this Section 6.4.4. Any remaining amounts
                           from such recovery shall be shared pro rata by the
                           Parties, based on the

                                       26
<Page>

                           portion of the expenses paid by each Party in
                           defending such suit and prosecuting such
                           counterclaims.

         6.5      CERTIFICATION UNDER DRUG PRICE COMPETITION AND PATENT
                  RESTORATION ACT. Apollo and AHPC each shall immediately give
                  written notice to the other of any certification of which they
                  become aware filed pursuant to 21 U.S.C. Section 355(b)(2)(A)
                  (or any amendment or successor statute thereto) claiming that
                  Apollo Patent Rights covering any Licensed Product or the use
                  of any Licensed Product in the Field are invalid or that
                  infringement will not arise from the manufacture, use or sale
                  of Licensed Product(s) by a Third Party. Notwithstanding any
                  provision to the contrary, in the event that Apollo has failed
                  to bring an infringement action against such Third Party at
                  least fourteen (14) days prior to expiration of the forty five
                  (45) day period set forth in 21 U.S.C. Section 355(c)(3)(C)
                  (or any amendment or successor statute thereto), AHPC shall
                  have the right to bring such an infringement action, in its
                  sole discretion and at its own expense, in its own name and/or
                  in the name of Apollo. At AHPC's request, Apollo shall provide
                  AHPC reasonable assistance to conduct such infringement
                  action, including, without limitation, causing the execution
                  of such legal documents as AHPC may deem necessary for the
                  prosecution of such action. AHPC shall periodically reimburse
                  Apollo for its out-of-pocket costs (excluding any of Apollo's
                  costs of retaining independent counsel) incurred in assisting
                  AHPC. AHPC shall incur no liability to Apollo as a consequence
                  of such litigation or any unfavorable decision resulting
                  therefrom, including any decision holding any of the Apollo
                  Patent Rights invalid or unenforceable. In the event that AHPC
                  recovers any sums in such litigation by way of damages or in
                  settlement thereof, AHPC shall have the right to retain all
                  such sums to offset its costs, losses and expenses.

         6.6      ABANDONMENT. Subject to AHPC's rights pursuant to Section 6.2,
                  Apollo shall at the earliest known date give notice to AHPC of
                  the grant, lapse, revocation, surrender, invalidation of
                  abandonment of any Apollo Patent Rights licensed to AHPC for
                  which Apollo is responsible for the filing, prosecution and
                  maintenance under this Agreement.

         6.7      PATENT TERM RESTORATION. Apollo shall have the right, in the
                  first instance, to determine whether to seek patent term
                  restoration (or its equivalent) with respect to any Apollo
                  Patent Right and shall notify AHPC, in writing, as to whether
                  or not Apollo has elected to seek such patent term restoration
                  (or its equivalent), provided, however, that in the event
                  Apollo has elected not to seek such patent term restoration
                  (or its equivalent), such written notice must be delivered to
                  AHPC no later than ninety (90) days prior to the date that any
                  action must be taken in order to

                                       27
<Page>

                  preserve the ability to obtain such a patent term restoration
                  (or its equivalent). In the event that Apollo elects not to
                  seek patent term restoration (or its equivalent) with respect
                  to any Apollo Patent Right, AHPC shall have the right, but not
                  the obligation, to seek patent term restoration (or its
                  equivalent) for such Apollo Patent Right at its own expense,
                  PROVIDED, HOWEVER, that if AHPC does elect to seek such patent
                  term restoration (or its equivalent) with respect to such
                  Apollo Patent Right as permitted by this sentence, then, as of
                  the date such Apollo Patent Right would have otherwise expired
                  but for AHPC seeking such patent term restoration (or its
                  equivalent) such Apollo Patent Right shall no longer be
                  included within the definition of the Apollo Patent Rights
                  hereunder solely for the purpose of calculating royalties
                  payable under Section 3.9 hereof, but not for any other
                  purpose. In the event that either Party elects to seek patent
                  term restoration (or its equivalent) for any Apollo Patent
                  Right as provided in this Section 6.7, the Parties shall
                  cooperate with each other in obtaining such patent term
                  restoration (or its equivalent) which cooperation shall
                  include, without limitation, executing those documents that
                  may be necessary for either Party to seek and obtain such
                  patent term restoration (or its equivalent).

         6.8      NOTICES REGARDING PATENTS. All notices, inquiries and
                  communications in connection with this Article IV shall be
                  sent in the manner set forth in Section 13.7 to the Parties at
                  the addresses and facsimile numbers indicated below.

                  If to Apollo:             Apollo BioPharmaceutics, Inc.
                                            One Broadway
                                            Suite 600
                                            Cambridge, Massachusetts  02142
                                            Attn.:  President
                                            Fax No.:  (617) 621-7156

                           with a copy to:       Palmer & Dodge
                                                 One Beacon Street
                                                 Boston, Massachusetts  02108
                                                 Attn.: [ * CON * ]
                                                 Fax No.: (617) 227-4420

                  If to AHPC:               American Home Products Corporation
                                            One Campus Drive
                                            Parsippany, New Jersey 07054
                                            Attn.: Senior Vice President
                                            Patent and Trademark Department

                                       28
<Page>

                                            Fax No.: (973) 683-4121

7.       REPRESENTATIONS AND WARRANTIES.

         7.1      REPRESENTATIONS AND WARRANTIES OF BOTH PARTIES. As of the
                  Effective Date, each of Apollo and AHPC hereby represents,
                  warrants and covenants to the other Party hereto as follows:

                  (a)      it is a corporation or entity duly organized and
                           validly existing under the laws of the state or other
                           jurisdiction of incorporation or formation;

                  (b)      the execution, delivery and performance of this
                           Agreement by such Party has been duly authorized by
                           all requisite corporate action and do not require any
                           shareholder action or approval;

                  (c)      it has the power and authority to execute and deliver
                           this Agreement and to perform its obligations
                           hereunder;

                  (d)      the execution, delivery and performance by such Party
                           of this Agreement and its compliance with the terms
                           and provisions hereof does not and will not conflict
                           with or result in a breach of any of the terms and
                           provisions of or constitute a default under (i) a
                           loan agreement, guaranty, financing agreement,
                           agreement affecting a product or other agreement or
                           instrument binding or affecting it or its property;
                           (ii) the provisions of its charter or operative
                           documents or bylaws; or (iii) any order, writ,
                           injunction or decree of any court or governmental
                           authority entered against it or by which any of its
                           property is bound; and

                  (e)      it shall at all times comply with all applicable
                           material laws and regulations relating to its
                           activities under this Agreement, including, without
                           limitation, for all patent applications and patents
                           claiming inventions that are subject inventions (as
                           such term is defined in 37 CFR Section 401) of a
                           funding agreement between an agency of the united
                           States Government and [ * CON * ] or the [ * CON * ],
                           all rights and limitations of U.S. Code Title 35,
                           Chapter 38, and the implementing regulations thereof.

         7.2      REPRESENTATIONS AND WARRANTIES OF APOLLO. In addition to the
                  representations and warranties made by Apollo under Section
                  7.1 hereof, Apollo hereby represents and warrants to AHPC
                  that:

                                       29
<Page>

                  (a)      it has the full right, power and authority to grant
                           the licenses and options granted to AHPC under
                           Article 2 hereof;

                  (b)      all inventors (who are known as of the Effective
                           Date) of any inventions included within the Apollo
                           Patent Rights and the Know-How have assigned their
                           entire right, title and interest in and to such
                           inventions and the Apollo Patent Rights either to
                           Apollo or to the Third Party from whom Apollo has
                           obtained a license whereby Apollo Controls such
                           inventions or Apollo Patent Rights and, to the best
                           of Apollo's knowledge, such knowledge being
                           developed, at least in part, by due investigation by
                           Apollo, no person, other than those persons named as
                           inventors on any patent or patent application
                           included within the Apollo Patent Rights, is an
                           inventor of the invention(s) claimed in such patent
                           or patent application;

                  (c)      to the best of Apollo's knowledge, such knowledge
                           being developed, at least in part, by due
                           investigation by Apollo, the [ * CON * ] has (i)
                           complied with all of its obligations under applicable
                           United States Government laws and regulations with
                           respect to any inventions included within the Apollo
                           Patent Rights or the Know-How which inventions are
                           subject inventions of a funding agreement with the
                           United States Government or any agency thereof and
                           (ii) elected to retain title to any such invention as
                           provided in 37 CFR Part 401.

                  (d)      all Apollo Patent Rights that are existing as of the
                           Effective Date are listed on Exhibit A attached
                           hereto and to the best of Apollo's knowledge all such
                           Apollo Patent Rights are not invalid or
                           unenforceable, in whole or in part;

                  (e)      except as described in Section 7.4 hereof, it has
                           not, prior to the Effective Date, previously
                           assigned, transferred, conveyed or otherwise
                           encumbered its right, title and interest in any of
                           the Apollo Patent Rights or the Know-How;

                  (f)      as of the Effective Date, there are no claims,
                           judgments or settlements against or owed by Apollo
                           or, to the best of its knowledge, pending or
                           threatened claims or litigation relating to the
                           Apollo Patent Rights or the Know-How and during the
                           term of this Agreement Apollo shall promptly notify
                           AHPC, in writing, upon learning of any such actual or
                           threatened claim, judgment or settlement;

                  (g)      during the Term of this Agreement it will use
                           diligent efforts not to diminish the rights under the
                           Apollo Patent Rights or the Know-

                                       30
<Page>

                           How including, without limitation, by not committing
                           or permitting any actions or omissions which would
                           cause the breach of any agreements between itself and
                           Third Parties which provide for intellectual property
                           rights applicable to the development, manufacture,
                           use or sale of Licensed Products in the Field, and
                           that it will provide AHPC promptly with notice of any
                           such alleged breach, and that, as of the Effective
                           Date, it is in compliance in all material respects
                           with any agreements with Third Parties relating to
                           the Apollo Patent Rights and the Know-How;

                  (h)      as of the Effective Date, there are no collaborative,
                           licensing, material transfer, supply, distributorship
                           or marketing agreements or arrangements or other
                           similar agreements to which it or any of its
                           Affiliates is a party relating to the Apollo Patent
                           Rights, the Know-How or any Product, which agreements
                           are inconsistent with AHPC's rights hereunder;

                  (i)      it has not granted any rights to any Third Party with
                           respect to the Apollo Patent Rights, the Know-How or
                           any Product, which grant of rights would be
                           inconsistent with the rights granted to AHPC
                           hereunder; and

                  (j)      it has no knowledge of any material information,
                           other than information provided to AHPC in writing
                           prior to the signing of this Agreement, which would
                           negatively affect the ability of AHPC to obtain
                           Regulatory Approval for the use of any Licensed
                           Product in the Field or which would negatively affect
                           the timing for obtaining such Regulatory Approval.

         7.3      REPRESENTATION BY LEGAL COUNSEL. Each Party hereto represents
                  that it has been represented by legal counsel in connection
                  with this Agreement and acknowledges that it has participated
                  in the drafting hereof. In interpreting and applying the terms
                  and provisions of this Agreement, the Parties agree that no
                  presumption shall exist or be implied against the Party which
                  drafted such terms and provisions.

         7.4      PRIOR AGREEMENTS. Apollo had previously entered into
                  agreements with [ * CON * ] relating to all or part of the
                  Apollo Patent Rights and/or the Know-How. Additionally, Apollo
                  had previously entered into an agreement with [ * CON * ]
                  pursuant to which Apollo agreed, INTER ALIA, to pay to [ * CON
                  * ] a royalty based, in part, on payments Apollo receives from
                  licensing or otherwise transferring to other parties all or
                  part of the Apollo Patent Rights and/or Know-How. Apollo
                  represents and warrants to AHPC that the agreement with [ *
                  CON * ] including, without limitation, [ * CON * ], each have
                  no further right, title, interest or claim

                                       31
<Page>

                  in or to any Apollo Patent Right, the Know-How or any Licensed
                  Product. Apollo also represents and warrants to AHPC that the
                  agreement with [ * CON * ] other than Apollo, each have no
                  further right, title, interest or claim in or to any Apollo
                  Patent Right, the Know-How or any Licensed Product. Apollo
                  further represents and warrants to AHPC that, except for the
                  specific right to receive payments from Apollo in connection
                  with the Apollo Patent Rights, the Know-How and the Licensed
                  Products, [ * CON * ] has no other right, title, interest or
                  claim in or to any Apollo Patent Right, the Know-How or any
                  Licensed Product.

         7.5      APOLLO DISCLAIMER. APOLLO MAKES NO REPRESENTATION OR WARRANTY,
                  EITHER EXPRESS OR IMPLIED, THAT ANY MEHODS DESCRIBED IN THE
                  APOLLO PATENT RIGHTS OR KNOW-HOW WILL BE EFFECTIVE OR THAT ANY
                  OF THE LICENSED PRODUCTS WILL BE MERCHANTIBLE OR FIT FOR A
                  PARTICULAR PURPOSE.

8.       TERM AND TERMINATION.

         8.1      TERM AND EXPIRATION. This Agreement shall be effective as of
                  the Effective Date and unless terminated earlier by mutual
                  written agreement of the Parties or pursuant to Sections 8.2
                  or 8.3 below, the Term of this Agreement shall continue, on a
                  country-by-country and Licensed Product-by-Licensed Product
                  basis, in effect until expiration of the last to expire Patent
                  Right in such country incorporating a Valid Claim which
                  encompasses the composition or use of such Licensed Product in
                  the Field. Upon expiration of this Agreement AHPC's license to
                  use the Know-How pursuant to Section 2.1 hereof shall become a
                  fully paid-up, perpetual, irrevocable license.

         8.2      TERMINATION BY AHPC. AHPC may terminate this Agreement on a
                  Licensed Product by Licensed Product and on a country by
                  country basis at any time upon ninety (90) days prior written
                  notice to Apollo, provided, however that if AHPC elects to
                  terminate its rights and obligations under this Agreement with
                  respect to a Licensed Product in a Major Country, which
                  Licensed Product is then being marketed by AHPC, its
                  Affiliates or sublicensees in such Major Country, the notice
                  period set forth above in this Section 8.2 shall be extended
                  to three hundred sixty (360) days. Notwithstanding the
                  foregoing, in the event that AHPC learns of a lack of
                  efficacy, safety concerns or adverse regulatory actions
                  associated with such Licensed Product, AHPC may terminate this
                  Agreement with respect to such Licensed Product on a country
                  by country basis upon immediate written notice to Apollo.

         8.3      TERMINATION BY APOLLO FOR LACK OF DILIGENCE.

                                       32
<Page>

                  8.3.1    FAILURE TO USE COMMERCIALLY REASONABLE EFFORTS. If,
                           after the [ * CON * ] anniversary of the Effective
                           Date, AHPC commits a material breach of its
                           obligations under Section 4.1.1 hereof, and, after
                           the Parties have attempted to resolve any dispute
                           relating to such alleged breach, in good faith, in
                           accordance with the dispute resolution process set
                           forth in Section 11.7 hereof, AHPC, within ninety
                           (90) days after the date such dispute resolution
                           process is to be complete as provided in Section 11.7
                           hereof, fails to commence using Commercially
                           Reasonable Efforts to develop and apply for
                           Regulatory Approval for [ * CON * ] as required in
                           Section 4.1.1 hereof, , Apollo, as its sole and
                           exclusive remedy, may, upon thirty (30) days prior
                           written notice to AHPC, terminate this Agreement in
                           its entirety.

                  8.3.2    FAILURE TO FILE IND. In the event that AHPC has
                           exercised one or more of its options under Section
                           2.3 hereof and has failed to use its Commercially
                           Reasonable Efforts to file an IND for [ * CON * ]
                           within the time periods specified in either Section
                           4.1.2 or 4.1.3 , as applicable and as may be extended
                           pursuant to Section 4.2 hereof, Apollo may, as its
                           sole and exclusive remedy, terminate AHPC's license
                           under this Agreement with respect to such Product
                           Type by providing to AHPC, within sixty (60) days
                           after the expiration of the applicable time period
                           and any extensions thereof, written notice of such
                           termination.

         8.4      TERMINATION FOR CAUSE. Either Party may terminate this
                  Agreement with respect to a particular Product Type upon
                  written notice provided to the other Party at any time during
                  the Term :

                           (a)      if the other Party commits a material breach
                                    of its obligations, other than AHPC's
                                    obligations under Section 4.1.1 hereof,
                                    relating to such Product Type under this
                                    Agreement, and, after the Parties have
                                    attempted to resolve any dispute relating to
                                    such alleged breach, in good faith, in
                                    accordance with the dispute resolution
                                    process set forth in Section 11.7 hereof,
                                    such breach remains uncured for ninety (90)
                                    days measured from the date such dispute
                                    resolution process is to be complete as
                                    provided in Section 11.7 hereof, PROVIDED,
                                    HOWEVER, that if such breach is not
                                    susceptible of cure within such ninety (90)
                                    day period and the breaching Party uses
                                    diligent good faith efforts to cure such
                                    breach, such ninety (90) day period shall be
                                    extended to one hundred eighty (180) days;
                                    or

                                       33
<Page>

                           (b)      upon the filing or institution of
                                    bankruptcy, reorganization, liquidation or
                                    receivership proceedings, or upon an
                                    assignment of a substantial portion of the
                                    assets for the benefit of creditors by the
                                    other Party, or in the event a receiver or
                                    custodian is appointed for such Party's
                                    business, or if a substantial portion of
                                    such Party's business is subject to
                                    attachment or similar process; PROVIDED,
                                    HOWEVER, that in the case of any involuntary
                                    bankruptcy proceeding such right to
                                    terminate shall only become effective if the
                                    proceeding is not dismissed within sixty
                                    (60) days after the filing thereof.

         8.5      EFFECT OF TERMINATION.

                  8.5.1    TERMINATION BY AHPC. In the event AHPC terminates
                           this Agreement under Section 8.4(a), AHPC's licenses
                           pursuant to Sections 2.1 and 2.2 with respect to the
                           Product Type as to which the breach relates shall
                           become fully paid-up, perpetual, irrevocable
                           licenses, PROVIDED, HOWEVER, with respect to any of
                           the said licenses granted to AHPC herein pursuant to
                           any Apollo Patent Right that is Controlled by Apollo
                           by virtue of the license granted by [ * CON * ] AHPC
                           shall, upon conversion of this license to a direct
                           license with [ * CON * ] pursuant to Section 2.5
                           hereof, become obligated to pay to [ * CON * ] the
                           portion of the license fees and royalties that Apollo
                           would have received from AHPC and would have been
                           obligated to pay, but had not yet paid, to [ * CON *
                           ] pursuant to [ * CON * ] had this Agreement not been
                           so terminated.

                  8.5.2    TERMINATION BY APOLLO.

                           (a)      In the event that Apollo terminates this
                                    Agreement with respect to one or more
                                    Product Type(s) under either Section 8.3.1
                                    or 8.4(a) hereof, then the rights and
                                    licenses granted to AHPC under Section 2.1
                                    of this Agreement with respect to such
                                    Product Type(s) shall terminate and all
                                    rights to the Apollo Patent Rights and
                                    Apollo Know-How with respect to Licensed
                                    Products included within such Product
                                    Type(s) shall revert to Apollo.

                           (b)      In the event that Apollo terminates this
                                    Agreement with respect to one or more
                                    Product Type(s) under Section 8.3.2 hereof,
                                    then the rights and licenses granted to AHPC
                                    under Section 2.1 of this Agreement with
                                    respect to such Product

                                       34
<Page>

                                    Type(s) shall terminate and all rights to
                                    the Apollo Patent Rights and Apollo Know-How
                                    with respect to Licensed Products included
                                    within such Product Type(s) shall revert to
                                    Apollo. Additionally, in the event Apollo
                                    has terminated this Agreement under either
                                    Section 8.3.2 or Section 8.4(a) hereof with
                                    respect to Type D Products or Type E
                                    Products, AHPC shall provide Apollo with and
                                    Apollo shall have the right to use any
                                    preclinical or clinical test data that AHPC
                                    has generated with respect to such Licensed
                                    Products and AHPC will assign to Apollo all
                                    Regulatory Approvals and applications for
                                    Regulatory Approval for such Licensed
                                    Products, PROVIDED, HOWEVER, that AHPC SHALL
                                    PROVIDE NO REPRESENTATION OR WARRANTY OF ANY
                                    KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
                                    LIMITATION WARRANTIES OF MERCHANTABILITY AND
                                    FITNESS FOR A PARTICULAR PURPOSE, WITH
                                    RESPECT TO SUCH TEST DATA, REGULATORY
                                    APPROVALS OR APPLICATIONS FOR REGULATORY
                                    APPROVAL AND APOLLO'S USE OF ANY SUCH TEST
                                    DATA, REGULATORY APPROVALS, AND APPLICATIONS
                                    FOR REGULATORY APPROVAL SHALL BE AT APOLLO'S
                                    SOLE RISK.

                  8.5.3    EFFECT OF BANKRUPTCY. In the event AHPC terminates
                           this Agreement under Section 8.4(b) or this Agreement
                           is otherwise terminated under Section 8.4(b), the
                           Parties agree that AHPC, as a licensee of rights to
                           intellectual property under this Agreement, shall
                           retain and may fully exercise all of its rights and
                           elections under Title 11, including as set forth in
                           Section 11.8 hereof.

         8.6      SURVIVAL OF OBLIGATIONS. Expiration or termination of the
                  Agreement shall not relieve the Parties of any obligation
                  accruing prior to such expiration or termination, and the
                  provisions of Articles 9 and 10 and Sections 3.11, 5.2 and
                  11.6 shall survive the expiration or any termination of the
                  Agreement. Except as otherwise expressly provided herein, any
                  expiration or early termination of this Agreement shall be
                  without prejudice to the rights of either Party against the
                  other accrued or accruing under this Agreement prior to
                  termination, including the obligation to pay royalties for
                  Licensed Product(s) sold prior to such termination.

9.       INDEMNIFICATION AND INSURANCE.

         9.1      INDEMNIFICATION BY AHPC. AHPC shall indemnify, defend and hold
                  harmless (i) Apollo and its Affiliates, and each of its and
                  their respective

                                       35
<Page>

                  employees, officers, directors and agents and (ii) [ * CON *
                  ], and those inventors of any Apollo Patent Right which is
                  Controlled by Apollo by virtue of the license granted to it by
                  [ * CON * ] which inventors were employees of [ * CON * ] at
                  the time the inventions claimed in such Apollo Patent Rights
                  were made and have assigned their entire right, title and
                  interest in and to such Apollo Patent Rights to [ * CON * ]
                  (each of (i) and (ii), an "Apollo Indemnified Party") from and
                  against any and all liability, loss, damage, cost, and expense
                  (including reasonable attorneys' fees) to any Third Party
                  (collectively, a "Liability") which the Apollo Indemnified
                  Party may incur, suffer or be required to pay resulting from
                  or arising in connection with (i) the breach by AHPC of any
                  representation or warranty contained in Article 7 of this
                  Agreement; (ii) the manufacture, use or sale of Licensed
                  Products by AHPC; or (iii) the successful enforcement by an
                  Apollo Indemnified Party of its rights under this Section 9.1.
                  Notwithstanding the foregoing, AHPC shall have no obligation
                  under this Agreement to indemnify, defend or hold harmless any
                  Apollo Indemnified Party with respect to claims, demands,
                  costs or judgments which result from willful misconduct or
                  negligent acts or omissions of any Apollo Indemnified Party.

         9.2      INDEMNIFICATION BY APOLLO. Apollo shall indemnify, defend and
                  hold harmless AHPC and its Affiliates, and each of its and
                  their respective employees, officers, directors and agents
                  (each, an "AHPC Indemnified Party") from and against any
                  Liability which the AHPC Indemnified Party may incur, suffer
                  or be required to pay resulting from or arising in connection
                  with (i) the breach by Apollo of any representation or
                  warranty contained in Article 7 of this Agreement; (ii) any
                  negligent act or omission or intentional misconduct by Apollo
                  or any of its Affiliates in performing any of its obligations
                  hereunder; or (iii) the successful enforcement by an AHPC
                  Indemnified Party of its rights under this Section 9.2.
                  Notwithstanding the foregoing, Apollo shall have no obligation
                  under this Agreement to indemnify, defend, or hold harmless
                  any AHPC Indemnified Party with respect to claims, demands,
                  costs or judgments which result from willful misconduct or
                  negligent acts or omissions of AHPC, its Affiliates, or any of
                  their respective employees, officers, directors or agents.

         9.3      CONDITIONS TO INDEMNIFICATION. The obligations of the
                  indemnifying Party under Sections 9.1 and 9.2 are conditioned
                  upon the delivery of written notice to the indemnifying Party
                  of any potential Liability promptly after the indemnified
                  Party becomes aware of such potential Liability. The
                  indemnifying Party shall have the right to assume the defense
                  of any suit or claim related to the Liability if it has
                  assumed responsibility for the suit or claim in writing;
                  however, if in the reasonable judgment of the

                                       36
<Page>

                  indemnified Party, such suit or claim involves an issue or
                  matter which could have a materially adverse effect on the
                  business operations or assets of the indemnified Party, the
                  indemnified Party may waive its rights to indemnity under this
                  Agreement and control the defense or settlement thereof, but
                  in no event shall any such waiver be construed as a waiver of
                  any indemnification rights such Party may have at law or in
                  equity. If the indemnifying Party defends the suit or claim,
                  the indemnified Party may participate in (but not control) the
                  defense thereof at its sole cost and expense.

         9.4      SETTLEMENTS. Neither Party may settle a claim or action
                  related to a Liability without the consent of the other Party,
                  if such settlement would impose any monetary obligation on the
                  other Party or require the other Party to submit to an
                  injunction or otherwise limit the other Party's rights under
                  this Agreement. Any payment made by a Party to settle any such
                  claim or action shall be at its own cost and expense.

         9.5      LIMITATION OF LIABILITY. With respect to any claim by one
                  Party against the other arising out of the performance or
                  failure of performance of the other Party under this
                  Agreement, the Parties expressly agree that the liability of
                  such Party to the other Party for such breach shall be limited
                  under this Agreement or otherwise at law or equity to direct
                  damages only and in no event shall a Party be liable for,
                  punitive, exemplary or consequential damages. The limitations
                  set forth in this Section 8.5 shall not apply with respect to
                  the obligations of either Party to indemnify the other under
                  Sections 8.2 or 8.3 hereof in connection with a Liability to a
                  Third Party.

         9.6      INSURANCE. Apollo shall obtain and maintain at all times
                  during the term of this Agreement, Commercial General
                  Liability Insurance, including contractual liability coverage,
                  with reputable and financially secure insurance carriers, with
                  limits of not less than [ * CON * ] dollars ($[ * CON * ]) per
                  occurrence and in the aggregate. Additionally, if AHPC
                  exercises its option(s) under either Section 2.3.2 (with
                  respect to Type D Products) or 2.3.3 hereof (with respect to
                  Type E Products), at the earlier of (i) such time as human
                  clinical trials are initiated by or on behalf of AHPC for any
                  Type D Product or Type E Product, as applicable, or (ii) the
                  first Regulatory Approval is obtained for such a Type D
                  Product or Type E Product, as applicable, Apollo also shall
                  obtain and thereafter maintain Product Liability Insurance,
                  with reputable and financially secure insurance carriers, such
                  that the limits of Apollo's Commercial General Liability
                  Insurance, including Products Liability Insurance, are not
                  less than [ * CON * ] dollars ($[ * CON * ]) per occurrence
                  and in the aggregate. Apollo agrees that each such insurance
                  policy shall name

                                       37
<Page>

                  AHPC as an additional insured and shall contain a provision
                  requiring ten (10) day advance notification to AHPC in the
                  event of its cancellation or termination. Within thirty (30)
                  days after obtaining each such insurance policy as required
                  under this Section 9.6, Apollo shall provide to AHPC a
                  certificate of insurance or other evidence (reasonably
                  acceptable to AHPC) of such insurance.

10.      CONFIDENTIALITY.

         10.1     NONDISCLOSURE OBLIGATION. Each of Apollo and AHPC shall use
                  only in accordance with this Agreement and shall not disclose
                  to any Third Party any information including, without
                  limitation, Know-How, received by it from the other Party (the
                  "Information"), without the prior written consent of the other
                  Party. The foregoing obligations shall survive the expiration
                  or earlier termination of this Agreement for a period of [ *
                  CON * ] ([ * CON * ]) years. These obligations shall not apply
                  to Information that:

                           (i)      is known by the receiving Party at the time
                                    of its receipt, and not through a prior
                                    disclosure by the disclosing Party, as
                                    documented by business records;

                           (ii)     is at the time of disclosure or thereafter
                                    becomes published or otherwise part of the
                                    public domain without breach of this
                                    Agreement by the receiving Party;

                           (iii)    is subsequently disclosed to the receiving
                                    Party by a Third Party who has the right to
                                    make such disclosure;

                           (iv)     is developed by the receiving Party
                                    independently of the Information received
                                    from the disclosing Party and such
                                    independent development can be documented by
                                    the receiving Party; or

                           (v)      is required by law, regulation, rule, act or
                                    order of any governmental authority or
                                    agency to be disclosed by a Party, PROVIDED
                                    that notice is promptly delivered to the
                                    other Party in order to provide an
                                    opportunity to seek a protective order or
                                    other similar order with respect to such
                                    Information and thereafter the disclosing
                                    Party discloses to the requesting entity
                                    only the minimum Information required to be
                                    disclosed in order to comply with the
                                    request, whether or not a protective order
                                    or other similar order is obtained by the
                                    other Party.

                                       38
<Page>

         10.2     PERMITTED DISCLOSURES. Information may be disclosed to
                  employees or consultants of the receiving Party and, in the
                  case of AHPC, AHPC's Affiliates, but, in each case, only to
                  the extent required to accomplish the purposes of this
                  Agreement and only if the receiving Party obtains prior
                  agreement from such employees and consultants to hold in
                  confidence and not make use of such Information for any
                  purpose other than those permitted by this Agreement. Each
                  Party will use at least the same standard of care as it uses
                  to protect proprietary or confidential information of its own
                  to ensure that such employees, agents, consultants,
                  sublicensees or suppliers do not disclose or make any
                  unauthorized use of the Information.

         10.3     RETURN OF INFORMATION. If this Agreement is terminated for any
                  reason, then each Party, upon the request of the other Party,
                  shall return to such other Party all copies of Information
                  received from such other Party hereunder, provided, however,
                  that each Party's legal counsel may retain one copy of such
                  Information in a secure location solely for purposes of
                  determining such Party's continuing obligations hereunder.

         10.4     DISCLOSURE OF AGREEMENT. Neither Apollo nor AHPC shall release
                  to any Third Party or publish in any way any non-public
                  information with respect to the terms of this Agreement or
                  concerning their cooperation without the prior written consent
                  of the other, which consent will not be unreasonably withheld
                  or delayed, provided, however, that either Party may disclose
                  the terms of this Agreement to the extent required to comply
                  with applicable laws, including without limitation the rules
                  and regulations promulgated by the United States Securities
                  and Exchange Commission and the Party intending to disclose
                  the terms of this Agreement shall provide the nondisclosing
                  Party an opportunity to review and comment on the intended
                  disclosure which is reasonable under the circumstances.
                  Notwithstanding the foregoing, Apollo, to the extent required
                  by [ * CON * ], may provide, to [ * CON * ] copies of the
                  royalty reports submitted by AHPC to Apollo under Section
                  3.10.1 hereof, provided, however, that in so disclosing such
                  reports to [ * CON * ] Apollo takes all reasonable actions
                  that are necessary to ensure that [ * CON * ] maintains the
                  confidentiality of such reports and all information contained
                  therein and does not disclose such reports or any information
                  contained therein to any Third Party or use such reports or
                  any information contained therein for any purpose other than
                  verifying the amount of royalties or other fees that are due
                  from Apollo to [ * CON * ] pursuant to the [ * CON * ].

         10.5     PUBLICITY. Subject to Section 10.4, all publicity, press
                  releases and other announcements relating to this Agreement or
                  the transactions contemplated hereby shall be reviewed in
                  advance by, and shall be subject

                                       39
<Page>

                  to the approval of, both Parties, which approval shall not be
                  unreasonably withheld or delayed.

11.      MISCELLANEOUS.

         11.1     FORCE MAJEURE. Neither Party shall be liable to the other for
                  delay or failure in the performance of the obligations on its
                  part contained in this Agreement if and to the extent that
                  such failure or delay is due to circumstances beyond its
                  control. It shall notify the other Party promptly should such
                  circumstances arise, giving an indication of the likely extent
                  and duration thereof, and shall use all Commercially
                  Reasonable Efforts to resume performance of its obligations as
                  soon as practicable.

         11.2     ASSIGNMENT.

                  11.2.1   ASSIGNMENT BY APOLLO. Apollo shall not assign this
                           Agreement or any of its rights or obligations
                           hereunder to any Third Party without the prior
                           written consent of AHPC, which consent may be
                           provided or withheld in AHPC's sole discretion.
                           Notwithstanding, the foregoing, subject to the prior
                           written consent of AHPC, which consent shall not be
                           unreasonably withheld, Apollo may assign this
                           Agreement or any of its rights or obligations
                           hereunder to any of its Affiliates, for so long as
                           they remain Affiliates; provided, however, that such
                           assignment shall not relieve Apollo of its
                           responsibilities for performance of its obligations
                           under this Agreement. Additionally, AHPC's consent
                           shall not be required in the event that Apollo
                           assigns this Agreement to a Third Party as a part of
                           a merger of Apollo, with or the sale of all of
                           Apollo's assets to such Third Party, provided,
                           however, that (i) within ten (10) days of signing an
                           agreement for such merger or sale, Apollo shall
                           provide AHPC with written notice thereof, specifying
                           to whom this Agreement is to be assigned and when
                           such assignment is to become effective and (ii) on
                           the effective date of such assignment, such Third
                           Party delivers to AHPC a signed agreement assuming
                           all of Apollo' obligations under this Agreement.

                  11.2.2   ASSIGNMENT BY AHPC. AHPC may assign this Agreement
                           and/or any of its rights or obligations hereunder to
                           any of its Affiliates or to any Third Party;
                           provided, that in the event of such an assignment, no
                           intellectual property rights of the assignee shall be
                           included in the technology to be licensed to Apollo
                           upon Apollo's exercise of its option hereunder. AHPC
                           shall promptly provide Apollo with written notice of
                           any such assignment.

                                       40
<Page>

                  11.2.3   BINDING NATURE OF ASSIGNMENT. This Agreement shall be
                           binding upon and inure to the benefit of the
                           successors and permitted assigns of the Parties. Any
                           assignment not in accordance with this Section 11.2
                           shall be void.

         11.3     NO WAIVER. The failure of either Party to require performance
                  by the other Party of any of that other Party's obligations
                  hereunder shall in no manner affect the right of such Party to
                  enforce the same at a later time. No waiver by any Party
                  hereto of any condition, or of the breach of any provision,
                  term, representation or warranty contained in this Agreement,
                  whether by conduct or otherwise, in any one or more instances,
                  shall be deemed to be or construed as a further or continuing
                  waiver of any such condition or breach, or of any other
                  condition or of the breach of any other provision, term,
                  representation or warranty hereof.

         11.4     SEVERABILITY. If a court or other tribunal of competent
                  jurisdiction should hold any term or provision of this
                  Agreement to be excessive, or invalid, void or unenforceable,
                  the offending term or provision shall be deleted or revised to
                  the extent necessary to be enforceable, and, if possible,
                  replaced by a term or provision which, so far as practicable
                  achieves the legitimate aims of the Parties.

         11.5     RELATIONSHIP BETWEEN THE PARTIES. Both Parties are independent
                  contractors under this Agreement. Nothing herein contained
                  shall be deemed to create an employment, agency, joint venture
                  or partnership relationship between the Parties hereto or any
                  of their agents or employees, or any other legal arrangement
                  that would impose liability upon one Party for the act or
                  failure to act of the other Party. Neither Party shall have
                  any express or implied power to enter into any contracts or
                  commitments or to incur any liabilities in the name of, or on
                  behalf of, the other Party, or to bind the other Party in any
                  respect whatsoever.

         11.6     CORRESPONDENCE AND NOTICES.

                  11.6.1   ORDINARY NOTICES. Correspondence, reports,
                           documentation, and any other communication in writing
                           between the Parties in the course of ordinary
                           implementation of this Agreement shall be delivered
                           by hand, sent by facsimile, or by airmail to the
                           employee or representative of the other Party who is
                           designated by such other Party to receive such
                           written communication.

                  11.6.2   EXTRAORDINARY NOTICES. Extraordinary notices and
                           communications (including, without limitation,
                           Apollo' exercise of its option, notices of
                           termination, force majeure, material breach, change
                           of address) shall be in writing and delivered by hand
                           or sent

                                       41
<Page>

                           by nationally recognized overnight delivery service,
                           prepaid registered or certified air mail, or by
                           facsimile confirmed by prepaid first class,
                           registered or certified mail letter, and shall be
                           deemed to have been properly served to the addressee
                           upon receipt of such written communication.

                  11.6.3   ADDRESSES. In the case of Apollo, the proper address
                           for communications shall be:

                                    Apollo BioPharmaceutics, Inc.
                                    One Broadway
                                    Suite 600
                                    Cambridge, MA  02142
                                    Attn: President
                                    Fax:  (617) 621-7156

                                    with a copy to:        Palmer & Dodge
                                                           One Beacon Street
                                                           Boston, MA 02108
                                                           Attn: [ * CON * ]
                                                           FAX:  (617) 227-4420

                           and it the case of AHPC, the proper address for
                           communications and for all payments shall be:

                                    Wyeth-Ayerst Laboratories
                                    555 East Lancaster Avenue
                                    St. Davids, Pennsylvania  19087
                                    Attn:  Senior Vice President,
                                           Global Business Development
                                    Fax:  (610) 688-9498

                                    with a copy to:

                                            American Home Products Corporation
                                            5 Giralda Farms
                                            Madison, New Jersey 07940
                                            Attn:  Senior Vice President and
                                                   General Counsel
                                            Fax: (973) 660-7156

         11.7     CHOICE OF LAW; DISPUTE RESOLUTION. This Agreement is subject
                  to and governed by the laws of the State of Delaware,
                  excluding its conflict of laws provisions. The Parties
                  recognize that a bona fide dispute as to certain matters may
                  from time to time arise during the term of this Agreement. In
                  the event of the occurrence of such a dispute either Party

                                       42
<Page>

                  may, by written notice to the other Party (which notice shall
                  specify, without limitation, the particulars of the dispute
                  and the relevant provisions of this Agreement relating to such
                  dispute), have such dispute referred to their respective
                  officers (designated below) or their successors for attempted
                  resolution by good faith negotiations within thirty (30)
                  calendar days after such notice is received. Said designated
                  officers are as follows:

                           For AHPC:        Senior Vice President
                                            Global Business Development
                                            Wyeth-Ayerst Laboratories

                           For Apollo:      Vice President, Business Development
                                            Apollo BioPharmaceutics, Inc.

                           In the event the designated officers are not able to
                  resolve such dispute through good faith negotiations within
                  such thirty (30) calendar day period, the dispute shall then
                  be referred to their respective officers (designated below) or
                  their successors for attempted resolution by good faith
                  negotiations within thirty (30) calendar days after the end of
                  the thirty (30) day period described above. Said designated
                  officers are as follows:

                           If the dispute relates to a scientific or development
                  matter:

                           For AHPC:        President
                                            Wyeth-Ayerst Research

                           For Apollo:      President
                                            Apollo BioPharmaceutics, Inc.

                           If the dispute relates to a commercial or business
matter:

                           For AHPC:        Executive Vice President
                                            American Home Products Corporation

                           For Apollo:      President
                                            Apollo BioPharmaceutics, Inc.

                  In the event the designated officers are not able to resolve
                  such dispute through good faith negotiations within such
                  thirty (30) calendar day period, either Party may pursue any
                  legal or equitable remedies available to it by filing a claim
                  in the state or federal courts of the state of Delaware and
                  each Party hereby consents to the jurisdiction of such court
                  and each Party hereby irrevocably waives its right to a jury
                  trial before such court. Notwithstanding the foregoing,
                  nothing in this Section 11.7 shall prohibit a Party from
                  seeking temporary or injunctive relief from a state or federal

                                       43
<Page>

                  court in Delaware pending the resolution of a dispute in
                  accordance with the provisions of this Section 11.7.
                  Notwithstanding the foregoing, none of the provisions of this
                  Section 11.7 shall apply if and to the extent that this
                  Agreement becomes a direct license between [ * CON * ] and
                  AHPC as provided in Section 2.5 hereof, PROVIDED, HOWEVER,
                  that [ * CON * ] and AHPC will use good faith efforts to have
                  any disputes between them resolved by their respective senior
                  management prior to seeking any remedies that may be available
                  through the courts.

         11.8     PROVISIONS FOR INSOLVENCY.

                  11.8.1   EFFECT ON LICENSES. All rights and licenses granted
                           under or pursuant to this Agreement by Apollo to AHPC
                           are, for all purposes of Section 365(n) of Title 11
                           of the United States Code ("Title 11"), licenses of
                           rights to "intellectual property" as defined in Title
                           11. Apollo agrees that AHPC, as licensee of such
                           rights under this Agreement shall retain and may
                           fully exercise all of its rights and elections under
                           Title 11. Apollo agrees during the Term of this
                           Agreement to create and maintain current copies or,
                           if not amenable to copying, detailed descriptions or
                           other appropriate embodiments, to the extent
                           feasible, of all such intellectual property. If a
                           case is commenced by or against Apollo under Title
                           11, Apollo (in any capacity, including
                           debtor-in-possession) and its successors and assigns
                           (including, without limitation, a Title 11 Trustee)
                           shall,

                                    (i)      as AHPC may elect in a written
                                             request, immediately upon such
                                             request:

                                            (A)      perform all of the
                                                     obligations provided in
                                                     this Agreement to be
                                                     performed by Apollo
                                                     including, where applicable
                                                     and without limitation,
                                                     providing to AHPC portions
                                                     of such intellectual
                                                     property (including
                                                     embodiments thereof) held
                                                     by Apollo and such
                                                     successors and assigns or
                                                     otherwise available to
                                                     them; or

                                            (B)      provide to AHPC all such
                                                     intellectual property
                                                     (including all embodiments
                                                     thereof) held by Apollo and
                                                     such successors and assigns
                                                     or otherwise available to
                                                     them; and

                                    (ii)    not interfere with the rights of
                                            AHPC under this Agreement, or any
                                            agreement supplemental hereto,

                                       44
<Page>

                                            to such intellectual property
                                            (including such embodiments),
                                            including any right to obtain such
                                            intellectual property (or such
                                            embodiments) from another entity.

                  11.8.2   RIGHTS TO INTELLECTUAL PROPERTY. If a Title 11 case
                           is commenced by or against Apollo, and this Agreement
                           is rejected as provided in Title 11, and AHPC elects
                           to retain its rights hereunder as provided in Title
                           11, then Apollo (in any capacity, including
                           debtor-in-possession) and its successors and assigns
                           (including, without limitation, a Title 11 Trustee)
                           shall provide to AHPC all such intellectual property
                           (including all embodiments thereof) held by Apollo
                           and such successors and assigns, or otherwise
                           available to them, immediately upon AHPC's written
                           request. Whenever Apollo or any of its successors or
                           assigns provides to AHPC any of the intellectual
                           property licensed hereunder (or any embodiment
                           thereof) pursuant to this Section 14.8, AHPC shall
                           have the right to perform the obligations of Apollo
                           hereunder with respect to such intellectual property,
                           but neither such provision nor such performance by
                           AHPC shall release Apollo from any such obligation or
                           liability for failing to perform it.

                  11.8.3   AHPC'S RIGHTS. All rights, powers and remedies of
                           AHPC provided herein are in addition to and not in
                           substitution for any and all other rights, powers and
                           remedies now or hereafter existing at law or in
                           equity (including, without limitation, Title 11) in
                           the event of the commencement of a Title 11 case by
                           or against Apollo. AHPC, in addition to the rights,
                           power and remedies expressly provided herein, shall
                           be entitled to exercise all other such rights and
                           powers and resort to all other such remedies as may
                           now or hereafter exist at law or in equity
                           (including, without limitation, Title 11) in such
                           event. The Parties agree that they intend the
                           foregoing AHPC rights to extend to the maximum extent
                           permitted by law, including, without limitation, for
                           purposes of Title 11:

                                    (i)      the right of access to any
                                             intellectual property (including
                                             all embodiments thereof) of Apollo,
                                             or any Third Party with whom Apollo
                                             contracts to perform an obligation
                                             of Apollo under this Agreement,
                                             and, in the case of the Third
                                             Party, which is necessary for the
                                             development, registration,
                                             manufacture and marketing of
                                             Licensed Compounds and/or Licensed
                                             Products; and

                                       45
<Page>

                                    (ii)    the right to contract directly with
                                            any Third Party described in (i) to
                                            complete the contracted work.

         11.9     EXPORT CONTROLS. AHPC hereby agrees that it shall not sell,
                  transfer, export or re-export any Licensed Product or related
                  information in any form, or any direct products of such
                  information, except in compliance with all applicable laws,
                  including the export laws of the United States Government and
                  any federal regulations implementing such laws. AHPC shall be
                  solely responsible for obtaining all licenses, permits or
                  authorizations required from the United States Government or
                  the government of any other nation for any such export or
                  re-export. Apollo agrees to provide AHPC with such assistance
                  as AHPC may reasonably request in obtaining such license,
                  permits or authorizations.

         11.10    NON-USE OF NAMES. AHPC shall not use Apollo's, [ * CON * ]
                  name or the names of either of such institution's employees or
                  any adaptation thereof, in any advertising, promotional or
                  sales literature without the prior written consent obtained
                  from Apollo, [ * CON * ], as applicable. Apollo shall not use
                  AHPC's name, the names of any of AHPC's Affiliates or the
                  names of any of their respective employees, or any adaptation
                  thereof, in any advertising, promotional or sales literature
                  without AHPC's prior written consent. Notwithstanding the
                  foregoing, to the extent permitted under Section 10.4 hereof,
                  AHPC and Apollo may each state that the [ * CON * ] and that
                  this Agreement are in effect.

         11.11    ENTIRE AGREEMENT; AMENDMENT. This Agreement and all the
                  covenants, promises, agreements, warranties, representations,
                  conditions and understandings contained herein sets forth the
                  complete, final and exclusive agreement between the Parties
                  and supersedes and terminates all prior and contemporaneous
                  agreements and understandings between the Parties, whether
                  oral or in writing. There are no covenants, promises,
                  agreements, warranties, representations, conditions or
                  understandings, either oral or written, between the Parties
                  other than as are set forth in this Agreement. No subsequent
                  alteration, amendment, change, waiver or addition to this
                  Agreement shall be binding upon the Parties unless reduced to
                  writing and signed by an authorized officer of each Party. No
                  understanding, agreement, representation or promise, not
                  explicitly set forth herein, has been relied on by either
                  Party in deciding to execute this Agreement.

         11.12    HEADINGS. The headings and captions used in this Agreement are
                  solely for the convenience of reference and shall not affect
                  its interpretation.

                                       46
<Page>

         11.13    COUNTERPARTS. This Agreement may be executed in one or more
                  counterparts each of which shall be an original and all of
                  which shall constitute together the same document.

         11.14    FURTHER ACTIONS. Each Party agrees to execute, acknowledge and
                  deliver such further instruments, and to do all other acts, as
                  may be necessary or appropriate in order to carry out the
                  purposes and intent of this Agreement including, without
                  limitation, any filings with any antitrust agency which may be
                  required.

         IN WITNESS WHEREOF, this Agreement has been executed by the duly
authorized representatives of the Parties as of the date set forth below.

AMERICAN HOME PRODUCTS CORPORATION           APOLLO BIOPHARMACEUTICS, INC.

--------------------------------------       ----------------------------------
Name:                                        Name:
Title:                                       Title:

                                       47
<Page>

    [CERTAIN MATERIAL (INDICATED BY A [*CON*]) HAS BEEN OMITTED FROM THIS
    DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION]

                                    EXHIBIT A
                             APOLLO PATENT RIGHTS

[ * CON * ]

                                      A-1
<Page>

                                    EXHIBIT B

          DEFINITION OF "ESTROGEN" EXCERPTED FROM U.S PATENT [ * CON * ]

[ * CON * ]

                                      B-1
<Page>

                                    EXHIBIT C

                  ADVERSE DRUG EXPERIENCE REPORTING PROCEDURES

[ * CON * ]

                                      C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]